Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27Feb 2020
A randomized, double -blind, placebo -controlled, multi -centre, sequential 
design, phase IIa study to evaluate safety and tolerability of epicardial 
injections of AZD8601 during coronary artery bypass grafting surgery
Sponsor: AstraZeneca AB, 151 85 Södertälje, Sweden
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
7 (100)updated, so that the unblinded Safety Review Committee included external experts and had 
decisio n right about the progress of the study . The process has been adjusted to meet this 
request.
It was also required to add Study  specific stopping criteria.
In addit ion, an unblinded Data Monitoring Group (DMG) has been added to enable i nternal  
clinical project and business decisio n separate from the study .
Secti ons 1.3, 1.4, 3.6 and 3.11 have been adjusted accordingly.
To increase operational feasibilit y for pati ent and si te staff, i t has been added that if a 
patient is referred to another hospital for the 15O PET assessment , CT can also be 
perform edthere.
Secti ons 4.1.3 , 4.3.2 , 4.3.3 and 5.3.1 have been adjusted accordingly.
A cross was missing in Table 1to indicate that Medical history  is to be checked on Visit 3, 
day -1. 
This has been adjusted accordingly in Section 4.
An erroneous sentence has been deleted in Section 7.1. Text previously indicated that each 
syringe woul d be labelled with a pat ient-specific dosing label in local language. Each 
syringe is not l abelled by  pharmacy personnel due to a combinat ion of sterilit y requirement 
and that sy ringes are too small to accommodate the la bels. 
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
8 (100)This Clinical Study  Protocol  has been subject to a peer review according to AstraZeneca 
Standard procedures. The Clinical Study  Protocol  is publicly  registered and the results are 
disclosed and/or published according to the AstraZeneca Global Policy  on Bi oethics and in 
compliance wi th prevailing laws and regulat ions. 
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
11 (100)If not otherwise specified, baseline refers to the last measurement prior to administration of 
investigat ional product.
Analysis of the primary variable(s)
Theanal
ysis and presentati on of  safety v ariables will be based on patients in the safet y 
analysis set. 
All safet y variables will be summarised by treatment groups and visit using descript ive 
statist ics (n, m ean, standard deviation [SD], median, minimum, and maximum for continuous 
data and abso lute and relat ive frequencies for categorical data).
AEs will be summarised by treatm ent group, treatment related and severit y bymeans of 
counts summaries by Medical Dict ionary for Regulatory Activities(MedDRA) System  
Organ Class and Preferred Term (PT) . 
Laboratory data for haematology and clinical chemistry will be summarized by treatm ent 
group and visit. The number and percentages of patients with haematology  and clinical  
chemistry  treatment em ergent l aboratory  changes wi th respect to normal ranges b etween 
baseline and post treatm ent will be tabulated. The incidence of markedly abnorm al values 
and changes from baseline in the ECG parameters will be summarised by treatme nt group . 
Categorical outliers may bepresented bynumbers but need to be considered in context of 
inclusio n/excl usion criteria.Physical examinat ion and vital signs variables will be 
summarised by treatm ent group.
Unless otherwise stated, the fo llowing rul es will  apply to any  repeated safet y assessments:
If the repeated measur ement of a specific parameter occurs prior to IP administration 
(Day  1), the l ast ob tained value prior to dosing will be used in the descriptive statist ics 
and in the calculat ion of changes from baseline.
Exploratory analysis 
The analysis and presentation of expl oratory variables will be based on patients in the 
exploratory analysis set. 
All exploratory  variables will be summarised by treatment group and visit using descript ive 
statist ics (n, mean, standard deviation [SD], median, minimum, and maximum and geom etric 
mean and geo metric SD if applicable for continuous data and absolute and relat ive frequencies 
for categori cal data). P -values will be unadjusted and tests will be two -sided.
Mean values per treatment will be plotted against visit.
Geom etric mean per treatment and individual plasma levels of VEGF- A will be plotted 
against time after dosing. Calculat ion of VEGF AUC -Area under the concentration -time 
curve (μm ol*h/L) will be done by  linear up/ l og down trapezoi dal summat ion. 
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
12 (100)Change f rom baseline will be analysed for all exploratory  variables wit h baseline and post -
dose m easurements. Change from baseline for some exploratory  variables will be analysed 
using Analysis o f Covariance ,(with treatm ent as fixed effect, patient as random effe ct and 
baseline value as covariates) or a repeated measurements model (with treatment, visit and 
treatm ent-by-visit interaction as fixed effects, baseline as covariate and patient as random 
effect). If an approximat ion of the variable of interest fo llows a log-norm al distribut ion rather 
than a norm al distribut ion, a logarithmic transformation of the variable of interest will be 
done. All variables that are transformed will be back transformed for reporting.
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
13 (100)TABLE OF CONTENTS PAGE
TITLE PAGE ................................
....................................................................... 1
VERSION HISTORY .......................................................................................... 2
CLINICAL STUDY PROTOCOL SYNOPSIS .................................................... 9
TABLE OF CONTENTS ................................................................................... 13
1. INTRODUCTION ............................................................................................. 21
1.1 Background and rationale for conducting this stu dy........................................... 21
1.2 Rationale for study  design, doses and control groups .......................................... 22
1.3 Benefit/risk and ethical assessment .................................................................... 22
1.3.1 Dosing rat ionale................................................................................................. 24
1.4 Study Design ...................................................................................................... 24
2. STUDY OBJECTIVES ...................................................................................... 28
2.1 Primary object ive............................................................................................... 28
2.2 Secondary  object ives (NA) ................................................................................. 28
2.3 Safety objectives (NA) ....................................................................................... 28
2.4 Exploratory  objectives ....................................................................................... 28
3. PATIENT SELECTION, E NROLMENT, RANDOMISAT ION, 
RESTRICTIONS, DISCONTINUATION AN D WITHDRAWAL ..................... 29
3.1 Inclusio n criteria................................................................................................ 29
3.2 Exclusio n criteria............................................................................................... 30
3.3 Patient enrolment and rando misat ion.................................................................. 32
3.4 Procedures for handling incorrectly enro lled or randomized pat ients.................. 33
3.5 Methods for assigning treatment groups ............................................................. 33
3.6 Methods for ensuring blinding ........................................................................... 33
3.7 Methods for unblinding ...................................................................................... 34
3.8 Restrictions ........................................................................................................ 34
3.8.1 Medicat ions restrictions ..................................................................................... 34
3.8.2 Dietary  restri ctions............................................................................................. 34
3.8.3 Alcoho l, Drugs of abuse, Tobacco and Caffeine Restrict ions.............................. 35
3.8.4 Exercise restrict ions........................................................................................... 35
3.8.5 Restrictions for male pat ients............................................................................. 35
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
14 (100)3.9 Discontinuati on of  investigat ional product ......................................................... 35
3.9.1 Procedures for discont inuat ion of a patient fro m investigational product ............ 36
3.10 Criteria for wi thdrawal ....................................................................................... 36
3.10.1 Screen failures ................................................................................................... 36
3.10.2 Withdrawal  of the inform ed consent ................................................................... 36
3.10.3 Specific withdrawal criteria between visit 2 and 3 .............................................. 37
3.11 Discontinuati on of  the study ............................................................................... 37
3.11.1 Safety Review .................................................................................................... 38
3.11.1.1 Safety Review Board ......................................................................................... 38
3.11.1.2 Safety Review Co mmit tee.................................................................................. 38
3.11.1.3 Data Monitoring Group ...................................................................................... 39
4. STUDY PLAN AND TIMIN G OF PROCEDURES ........................................... 39
4.1 Screening/Enro lment period ............................................................................... 48
4.1.1 Pre-study  screening ............................................................................................ 48
4.1.2 Visit 1 –Screening, enrolment and baseline assessments (Day  -90 to -15).......... 48
4.1.3 Visit 2 –Rando misation and baseline assessments (Day  -35 to -14)................... 48
4.1.3.1 Pre-operative cardio -thoraci c surgery  conference to deci de individual 
inject ion map ................................
..................................................................... 49
4.2 Treatment period ................................................................................................ 50
4.2.1 Visit 3 –CABG surgery  and IP administration (Day  -1 to Day  4)....................... 50
4.3 Follow-up peri od................................................................................................ 50
4.3.1 Visit 4 -Telephone contact follow -up (Day  14 ±2 days) ..................................... 50
4.3.2 Visit 5 –Follow -up (1 m onth ±3 day s)............................................................... 50
4.3.3 Visit 6 –Follow u p (3 m onths ±14 days) ............................................................ 51
4.3.4 Visit 7 –Final fo llow-up (6 m onths ±14 days) ................................................... 51
5. STUDY ASSESSMENTS .................................................................................. 51
5.1 Efficacy assessments (NA) ................................................................................. 52
5.2 Safety assessments ............................................................................................. 52
5.2.1 Laboratory  safet y assessments ............................................................................ 52
5.2.2 Physical examinat ion......................................................................................... 54
5.2.3 ECG ................................................................................................................... 54
5.2.4 Vital signs .......................................................................................................... 55
5.2.4.1 Pulse, pulse oximetry  and bl ood pressure ........................................................... 55
5.2.5 Other safet y assessments .................................................................................... 55
5.2.5.1 Hem operi cardium  and/or tam ponade assessment wit h echocardiography ........... 55
5.3 Other assessments .............................................................................................. 55
5.3.1 15O PET and CT angiogram .............................................................................. 55
5.3.2 Echocardi ography .............................................................................................. 56
5.3.2.1 Stress echocardiography and optional LAD CFVR ............................................. 56
5.3.3 Gyrocard iography .............................................................................................. 56
5.3.4 Clinical Outcome Assessments ........................................................................... 56
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
15 (100)5.3.4.1 Kansas Cit y Cardiomyopathy  Questi onnai re...................................................... 57
5.3.4.2 Seattl e Angina Quest ionnaire ............................................................................. 57
5.3.5 NYHA classificat ion.......................................................................................... 58
5.3.6 Digital 6-minute wal k test and Maximum continuously walked steps 
(opti onal)........................................................................................................... 58
5.3.7 Filming/photo of inject ion procedure ................................................................. 58
5.4 Pharmacokinet ics............................................................................................... 58
5.5 Pharmacodynamics ............................................................................................ 59
5.6 Genet ics............................................................................................................. 59
5.7 Biomarker analysis ............................................................................................. 59
5.7.1 Storage, re -use and destruction of bio logical  samples ......................................... 62
5.7.2 Labelling and shipment of bio logical samples .................................................... 62
5.7.3 Chain o f custody  of biological samples .............................................................. 62
5.7.4 Withdrawal  of Informed Consent for donated biological samples ....................... 62
6. SAFETY REPORTING AND MEDICAL MANAGEMENT ............................. 63
6.1 Definit ion of adverse events ............................................................................... 63
6.2 Definit ions of serious adverse event ................................................................... 63
6.3 Recording of adverse events ............................................................................... 64
6.3.1 Time period for collect ion of adverse events ...................................................... 64
6.3.2 Follow-up of  unreso lved adverse events ............................................................. 64
6.3.3 Variables ............................................................................................................ 64
6.3.4 Causalit y collection ............................................................................................ 65
6.3.5 Adverse events based on signs and symptoms .................................................... 66
6.3.6 Adverse events based on examinat ions and tests ................................................ 66
6.3.7 Hy’s Law ........................................................................................................... 66
6.4 Reporting of serious adverse events ................................................................... 66
6.5 Overdose ............................................................................................................ 67
6.6 Pregnancy .......................................................................................................... 67
6.6.1 Maternal exposure .............................................................................................. 68
6.6.2 Paternal  exposure ............................................................................................... 68
6.7 Medicat ion Error ................................................................................................ 68
6.8 Study  governance and oversight ......................................................................... 69
7. INVESTIGATIONAL PROD UCT AND OTHER TREATM ENTS ................... 70
7.1 Ident ity of investigational product(s) .................................................................. 70
7.2 Dose and treatment regimens ............................................................................. 70
7.3 Labelling ............................................................................................................ 70
7.4 Storage ............................................................................................................... 71
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
16 (100)7.5 Com pliance ................................
........................................................................ 71
7.6 Accountabilit y.................................................................................................... 71
7.7 Concomitant and other treatments ................................
...................................... 71
7.7.1 Other concomitant treatment .............................................................................. 71
8. STATISTICAL ANALYSES BY ASTRAZENECA .......................................... 71
8.1 Statistical considerat ions.................................................................................... 71
8.2 Sample size est imate .......................................................................................... 72
8.3 Definit ions of analysis sets ................................................................................. 72
8.3.1 Safety analysis set .............................................................................................. 72
8.3.2 Exploratory  analysis set ..................................................................................... 72
8.3.3 All Enrolled Patients .......................................................................................... 72
8.3.4 All Rando mized Patients .................................................................................... 73
8.4 Outcom e measures for analyses .......................................................................... 73
8.4.1 Safety variables .................................................................................................. 73
8.4.2 Exploratory  variables ......................................................................................... 73
8.4.3 Exploratory  biomarkers ...................................................................................... 74
8.5 Methods for statist ical analyses .......................................................................... 75
8.5.1 Analysis of the primary  variable (s) .................................................................... 75
8.5.2 Exploratory  analysis ........................................................................................... 76
9. STUDY AND DATA MANAGEMENT BY ASTRAZENECA ......................... 76
9.1 Training of study  site staff.................................................................................. 76
9.2 Moni toring of the study ...................................................................................... 76
9.2.1 Source data ........................................................................................................ 77
9.2.2 Study  agreem ents............................................................................................... 77
9.2.3 Archiving of study  docum ents............................................................................ 77
9.3 Study  timetable and end of study ........................................................................ 77
9.4 Data m anagement ............................................................................................... 78
10. ETHICAL AND REGULATO RY REQUIREMENTS ....................................... 78
10.1 Ethical conduct of the study ............................................................................... 78
10.2 Patient data protecti on........................................................................................ 79
10.3 Ethics and regulatory  review .............................................................................. 79
10.4 Inform ed consent ............................................................................................... 79
10.5 Changes to the Clinical Study  Protocol  and Informed Consent Form .................. 80
10.6 Audits and inspect ions....................................................................................... 80
11. LIST OF REFERENCES ................................................................................... 81
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
17 (100)LIST OF TABLES
Table 1 Schedule of Assessments: Enrolment and treatment periods .................. 40
Table 2 Schedule of assessments: Fo llow-up period ........................................... 45
Table 3 Standard Clinical Laboratory  Evaluat ion Panels .................................... 53
Table 4 Other Clinical Safet y Panels .................................................................. 53
Table 5 Exploratory  biomarkers ......................................................................... 60
Table 6 Invest igational products ........................................................................ 70
Table 7 Prohibited medicat ion........................................................................... 71
LIST OF FIGURES
Figure 1 Outline of sent inel dosing cohorts ......................................................... 26
Figure 2 Study  flow chart .................................................................................... 27
LIST OF APPENDICES
Appendix A Addit ional Safet y Informati on............................................................... 85
Appendix B International Airline Transportation Associat ion (IATA) 6.2 
Guidance Docum ent.............................................................................. 87
Appen dix C Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ........................................................................ 88
Appendix D Kansas Cit y Cardio myopathy  Questi onnai re......................................... 92
Appendix E Seattl e Angina Quest ionnaire ................................................................ 96
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
18 (100)LIST OF ABBREVIATION S AND DEFINITI ON OF TERMS
The fo llowing abbreviat ions and special terms are used in this study  Clinical Study  Protocol .
Abbreviation or 
special termExplanation
15O PET O-15 Radiowater Positron Emission Tomography
AE Adverse Event
ACE Angiotensin Converting Enzyme
ACS Acute Coronary Syndrome
ALP Alkaline phosphatase
ALT Alanine Aminotransferase
ARB Angiotensin Receptor Blocker
AST Aspartate aminotransferase
BP Blood Pressure
CABG Coronary Artery By -pass Grafting
CAD Coronary Artery Disease
 
CRF Case Report Form (electronic/paper)
CRO Contract Research Organisation
CSA Clinical Study Agreement
CSR Clinical Study Report
CT Computed Tomography
CTCAE Common Terminology Criteria for Adverse Event
d6MWT Digital 6 -minute Walking Test
DAE Discontinuation of Investigational Product due to Adverse Event
DGR Danger ous Goods Regulations
DILI Drug Induced Liver Injury
DMG Data Monitoring Group
DMP Data Management Plan
DNA Deoxyribonucleic acid 
EC Ethics Committee, synonymous to Institutional Review Board (IRB) and 
Independent Ethics Committee (IEC)
ECG Electrocardiogram

Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
19 (100)Abbreviation or 
special termExplanation
eCRF Electronic Case Report Form
EF Ejection Fraction
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
GMP Good Manufacturing Practice
HIV Hum an Immunodeficiency Virus
HR Heart Rate
hsTNT High- Sensitivity Troponin T
IATA International Airline Transportation Association
ICD Implantable Cardiac Defibrillator
ICF Infor med Consent Form
ICH International Conference on Harmonisation
International 
Co-ordinating 
investigatorIf a study is conducted in several countries the International Co -ordinating 
Investigator is the Investigator co -ordinating the investigators and/or 
activities internationally. 
IP Investigational Product 
ISRB Investigational Medicines Safety Review Board
KCCQ Kansas City Cardiomyopathy Questionnaire
LAD Left Anterior Descending 
LCA Left Coronary Artery
LCX Left Circumflex
LH Luteinizing Hormone
LIMS Laboratory Information Management System
LPLV Last Patient Last Visit
LV Left Ventricular
LVEDV Left Ventricular End -Diastolic Volume
LVEF Left Ventricular Ejection Fraction
LVESV Left Ventricular End -Systolic Volume
MCWS Maximum Continuously Walked Steps
MedDRA Medical Dictionary for Regulatory Activities 
modRNA Modified Ribonucleic Acid
MoP Manual of Procedures
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
20 (100)Abbreviation or 
special termExplanation
MPR Myocardial Perfusion Reserve
NA Not Applicable
NT-proBNP N-terminal pro b -type natriuretic peptide
NYHA New York Heart Association
OAE Other Significant Adverse Event
PD Pharmacodynamics
PET Positron Emission Tomography
PHL Potential Hy’s Law
PI Principal Investigator 
PK Pharmacokinetics
PR ECG interval measured from the onset of the P wave to the onset of the 
QRS complex
PRO Patient Reported Outcomes
QRS ECG interval measured from the onset of the QRS complex to the J point
QT ECG interval measured from the onset of the QRS complex to the end of 
the T wave
QTcF QT interval corrected for heart rate using Fridericia’s formula
R&D Research and Development
RCS Right Coronary Artery
RR The time between corresponding points on 2 consecutive R waves on ECG
SAE Serious Adverse Event 
SAP Statistical Analysis Plan
SAQ Seattle Angina Questionnaire
sMBF Stress Myocardial Blood Flow
SOC System Organ Class
SRB Safety Review Board
SRC Safety Review Committee
TBL Total Bilirubin
ULN Upper Limit of Normal
VEGF Vascular Endothelial Growth Factor
WBDC Web Based Data Capture
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
21 (100)1. INTRODUCTION
1.1 Background and rationale for conducting this study
Coronary  artery  disease (CAD) is characterized by obstructive atherosclerotic lesio ns in the 
arteri al wall resul ting in limitat ion in myocardial  blood fl ow, eventually leading to i schemia 
and ventricular dysfunct ion. In Global Burden of Di sease study  CAD affected 110 millio n 
peopl e globally and resul ted in 8.9 millio n deaths in 2015 making CAD the most commo n 
cause of death in a global scale. ( GBD 2015 Disease and Injury Incidence and Prevalence 
Collaborators 2016 , GBD 2015 Mortalit y and Causes of Death Co llaborators 2015) Besides 
the apparent acute coronary  syndrom e (ACS) and my ocardial  infarct ion, CAD is the primary  
single cause of left ventricular (LV) systolic dysfunct ion leading to heart failure, ( Task f orce 
for the di agnosis and treatm ent of  chronic heart failure, European Societ y of Cardi ology 2001 ) 
with reports suggesting CAD to be the primary  cause of heart failure in even close to 70% of 
cases ( Medical  Advisory  Secretari at 2010 ). According to recent trends in the United States, in 
individuals of 40 years and over, half of healthy men and one third of women develop CAD in 
their life time ( Rosam ond W et al. 2007 ). When comparing CAD to heart failure the risk o f 
heart failure is lower but with apparent ly more detrimental  progressi on of  disease -in 
popul ation of 40 y ears and over the lifet ime risk o f developing heart failure is 20% ( Djousse L 
et al. 2009 ) with approximate survival rate of 50% in 5 years’ time after diagnosis ( Go AS et 
al. 2013 ). Overall, CAD and heart failure are closely linked and left ventricular funct ion 
serves as an important determinant of prognosis and can be used to predict disease outcome. 
(Cohn JN et al 1993, Parameshwar J et al. 1997 ) Coronary  revasculari zation in many instances 
can relieve s ymptom s, improve prognosis and left ventricular funct ion and is therefore 
applicable therapy not only  in ACS but in symptomat ic stable CAD ( Stirrup J et al . 2017 ). 
However, in spite of medical advancements in treatment of especially ischemic heart failure, 
such as revascularizat ions (Stirrup J et al . 2017 ), beta -blockers ( Packer M et al. 1996 ), 
angiotensin -convert ing enzyme (ACE) inhibitors,( The CONSENSUS Trial Study  Group 
1987) angi otensin II inhibitors ( Pitt B et al . 1997 ) and aldosterone receptor blockade, as well 
as novel devices such as cardiac resynchronization therapy, ( Yancy  CW et al . 2013 ), there is a 
clear unmet m edical need in addressing the medical therapies for this pat ient populat ion.
Through stimulat ion of angiogenesis, especially arteriogenesis, therapeut ic vascular growth is 
emerging as a co ncept for management of vascular indications such as coronary ischemia, 
critical limb ischemia and chronic wounds. The vascular endothelial growth factor (VEGF) is 
a protein coded by  a 7-exon gene l ocalized on chromoso me 6 and serves as a major angiogen 
innorm al cardiac devel opment (
Ferrara N et al. 1991). The VEGF gene is normally spliced 
into 4 different form s; of these, VEGF121 (containing 121 amino acids) and VEGF165 (165 
amino acids) appear to be the most important. 
The VEGF family  members are key  regul ators of vascular growth and the VEGF -A member, 
and especially  its 165 amino acid l ong primary isoform  (VEGF165), administered as 
recombinant prote in or via naked or adenoviral vector- mediated gene transfer has received 
much attenti on for its poten tial beneficial effects in cardiovascular medicine. However, 
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
22 (100)rando mized controlled trials have not lived up to expectations and evidence o f clinical 
effica cy is inconcl usive.
The overall reason(s) for the lack of consistency and conclusive clinical benefit is current ly 
somewhat unclear but may include factors such as suboptimal pharmacokinet ics (PK) and 
local concentrati ons of the protein, poor gene transfer efficiency , inappropri ate dosing and 
regression o f immature vessels, prolonged expression of the paracrine factor as well as growth 
factor -related adverse effects such as oedema and hypotension. To circumvent the issues 
associ ated wi th recombinant protein and gene transfer modalit ies, synthet ic and chemically 
modified mRNA (modRNA) has been put forward as a non -immunogenic and non -integrating 
modality for efficient and transient expressio n of target proteins in mammalian cells. 
AZD8601 is VEGF -A165 modRNA under development as a novel modalit y for local 
producti on of  human VEGF -
A protein and is developed for the treatment of ischemic heart 
disease.
1.2 Rationale for study design, doses and control groups
This study  is a randomized, double -blind, pl acebo -controlled, mult icenter, sequent ial design 
study  to assess the safet y and tol erabilit y of AZD8601 versus placebo. Placebo has been 
chosen as the comparator to assess safet y and tol erabilit y of both inject ion procedure and 
AZD8601. Parameters for potential efficacy will be addressed under explorative endpo ints. 
The study  examines the effects of AZD8601 given as epicardial inject ions in patients with 
stable CAD with decreased left ventricular ejection fract ion (LVEF) going through elect ive 
CABG. Prior to CABG, each pat ient will undergo a O -15 radio -water positron emissio n 
tomography  (PET)/ Com puted Tom ography  (CT) scan, which generates a combined image of 
coronary  angiogram superimposed on a my ocardial  perf usion map to l ocate areas of 
myocardial  ischemia and dysfunction. Whilst ischemic LV systolic dysfunct ion may be due to 
myocardial  damage, i t may also resul t from the presence of dysfunct ional, but viable, 
myocardium . Such viable t issue, associated with reduc ed perfusio n and diminished 
contractilit y at rest that recovers funct ion upon revascularizat ion, has been co mmo nly referred 
to as hibernat ing myocardi um ( Rahim toola SH 1985 , Rahimtoola SH 1989). 
Revascularizat ion can reach and improve funct ion of hibernat ing myocardi um but most of ten 
it may not be able to recover full physio logic functi onality. Primarily  the safet y and 
tolerabilit yof AZD8601 in increasing doses in patients going through CABG will be assessed. 
In addit ion, exploratory object ives that address the capabilit ies of AZD8601 to improve global 
and local myocardial perfusio n and/or left ventricle function in the studied pat ient cohort will 
be explored. For this purpose a PET camera will be utilized to detect changes in myocardial 
perfusio n, and ventricular wall mot ion (Saraste A et el. 2017 ) will primarily be assessed by 
echocardiography. 
1.3 Benefit/risk and ethical assessment
This is a first time in pat ient Phase IIa study  aiming to show the safet y and tol erabili ty of 
epicardial injections of AZD8601 in pat ients with ischemic heart disease undergoing CABG 
surgery  and wi th moderately impaired systolic function. The study  durati on wi th follow-up 
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
23 (100)until 6 months post CABG surgery is expected to be of sufficient length to permit evaluat ion 
of the drug’s safet y and tol erabili ty profile on top of standard of care in CAD patients to 
support further clinical development. As explorat ive object ives, potential effects of VEGF -A 
RNA (AZD8601) on regional and glo bal stress my ocardial  blood fl ow (sMBF) and 
myocardial  perf usion reserve ( MPR) and cardiac funct ion will be explored.
A pri or Phase I study  has been conducted invest igating AZD8601 induced intradermal VEGF 
producti on which suggested a well -tolerated safet y profile. There were no apparent clinically 
relevant trends in blood press ure, heart rate, ECG or laboratory  variables, including liver 
safet y parameters. Thi s is in line with prior safet y data covering over 10 y ears’ fo llow
-ups in 
patients wi th prior treatm ent wi th VEGF m odali ties (Hedm an et al . 2009 , Muona K et al. 
2012, Ro sengart TK et al. 2013 ). The preclinical safet y findings are described in detail in the 
Invest igators Brochure. Based on knowledge of the mechanism o f action, previ ous clinical  
experience and the preclinical safet y studi es the potential risks will be closely  monitored. 
No spec ific harms are ant icipated fro m participat ing in this trial. Available preclinical and 
clinical data suggest that the patients may benefit from participat ion in the study as 
administration of VEGF -A RNA m ay im prove LVEF. In m ore detail, functional act ivity 
of the AZD8601 -produced protein was demo nstrated as substant ia
l phosphorylat ion of the 
VEGF receptor 2 was seen in human umbilical vein endothelial cells exposed to condit ioned 
medium harvested fro m cells transfected with AZD8601. Furthermore, AZD8601 -produced 
VEGF -A protein was found to induce angiogenesis as evidenced by a trend towards increased 
total tube area and number of branch points to a similar extent as seen in cells exposed to 
human recombinant VEGF -A protein. VEGF- A modRNA given as epicardi al inject ion has 
been shown to improve cardiac funct ion in several animal models of myo cardial  infarcti on, 
ranging from mice ( Zangi L et al. 2013 ), rat and pig. Preclinical toxico logical study  in pig 
model of myocardial  infarcti on did not gi ve rise to any safet y concerns (see IB). Further, in an 
ongoing phase I trial where AZD8601 is administered as intradermal injections, AZD8601 
was well tol erated wi thout SAEs. In terms of AEs the most commo n was local transient 
inject ion site reaction which is completely reversible (see IB). 
Pharmaceut ical therapy administered directly in to myocardium can be administered through 
several different techniques, such as epicardial, endocardial, intracoronary  or coronary  sinus 
approaches. For accuracy  and reliabilit y the epicardi al approach has been considered as 
method of cho ice, although its invasive nature and possible induct ion of arrhyt hmias balance 
the scale in compa rison to other available administ ration m odali ties (Dib N et al. 2011). Due 
to this essent ial and invasive nature of epicardial inject ions in this stu dy placebo vehicles will 
be injected to different iate fro m possible drug delivery -related effects. To be able to evaluate 
potenti al beneficial effects of AZD8601 per se, placebo inject ions are considered to be 
necessary  in the study  design ( Mathiasen A et al. 2015 ). The selected placebo controlled 
design also enables further different iation with infrequent but possible adverse effects such as 
pericardia l effusi on, e.g. for VEGF in individual cases has been associated with pericardial 
effusio ns (Karatolio s et al . 2012 ).

Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
25 (100)Patients sui table for the study  will be ident ified by screening of hospital medical records of 
patients scheduled for elective CABG surgery  with an expected wait ing time to surgery less 
than 3 m onths but more than 2 weeks. If a patient is found potentially suitable, he/she will be 
asked about participat ion in this study and invit ed to a screening/enrolment visit (Visit 1). 
Before any  study  related procedures are conducted, the patient will receive informa tion about 
the study  and will  be asked to si gn Informed Consent Form (ICF). The patients will then 
undergo baseline assessments (Visit 1 and Visit 2). Further details are given in Sect ion 4.
To achieve 7 evaluable pat ients in each treatment group (low dose, high dose and placebo), 21 
in total –24 pati ents will init ially be randomized. An evaluable pat ient is defined as a patient 
who has co mpleted th e study .
The study  will include two cohorts of 12 patients each, which will receive either a low or high 
dose of AZD8601 (see Section 7.2) in a seq uential, dose ascending fashio n. Wit hin each 
cohort 8 patients will be rando mized to receive AZD8601 and 4 to placebo. 
Each cohort will be divided into 3 sentinel dosing cohorts. See Figure 1. The two first will 
include 2 patients each –1 patient randomized to placebo and 1 to AZD8601. The third 
sentinel cohort will include the 8 remaining patients on that dose level; 2 placebo, 6 
AZD8601. After each sentinel cohort, before proceeding dosing the next, safety data fro m up 
to 1 m onth post dose (Visit 5) fro m the current cohort and the available data from previous 
cohorts, will be reviewed. The same applies before continuing to the high dose cohort. The 
procedure will be repeated in the same way  within the high dose cohort. 
Two parallel safet y reviews will be done:
Blinded safet y review board (SRB) consist ing of study  invest igators and AZ 
personnel 
Study  independent unblinded safet y review co mmittee (SRC ) consist ing of a 
combinat ion of internal AZ expert ise and external experts
In addit ion, to the exist ing blinded and unblinded safet y review after each sentinel cohort, an 
additional unblinded Data Moni toring Group (DMG) will perform data review on emerging 
safet y and clinical data. This DMG will consist of internal AstraZeneca emplo yees 
independent of the study  team . Internal
 clinical  project and business decision separated from 
the study  will be considered for the clinical develo pment program .
This is further described in Sect ion 3.11.1 .
For treatm ent assi gnment see Secti on 3.5.
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
26 (100)Figure 1 Outline of sentinel dosing cohorts
Patients will  be followed up at 2 weeks, 1 month, 3 months, and 6 months post CABG 
surgery .
The Study  flow chart i s presented in Figure 2below. For details and timings of the study  
assessments refer to Table 1and Table 2in Section 4.1 lowdose
1 placebo
1 month8 pati ents
(6 lowdose/
2 placebo)1 highdose
1 placebo1 highdose
1 placebo8 patients
(6 highdose/
2 placebo)
Safet yreview1 month
Safety review Safet yreview Safe tyreview Safe tyreview1 month 1 month1 lowdose
1 placebo
1 monthLow dose AZD8601 
cohortHigh dose AZD8601 
cohort
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
27 (100)Figure 2 Study flow cha rt
TC = telephone contact; CABG = coronary artery bypass grafting; IP = investigational product, AZD8601 or placebo; m = month2 weekTC
follow -upRandomiz ationEnrolment & 
Informed Conse ntCABG
& IP 
adminis tration1 m 
follow -up3 m 
follow-up6 m 
follow -upVisit 1                     V isit 2                 V isit 3            V isit 4            V isit 5                          V isit6                        V isit 7
Day -90 to -15          Day -35 to -14         Day -1 to 4            2 weeks 1 mont h 3 months 6 mont hs
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
29 (100) To determine the VEGF -A protein concentration in plasma in pat ients undergo ing 
CABG surgery , after epicardial  inject ions of AZD8601 or placebo
 To collect samples for exploratory  research aimed at i nvest igating bio markers 
including but not limited to VEGF -A downstream bio markers invo lved in PK, 
pharmacodynamics (PD), efficacy, safet y and tol erabilit y related to AZD8601 
treatm ent. 
 To collect and store samples for futur e potential exploratory  determinati on of   
plasma concentrations of VEGF -A RNA (AZD8601) after epicardial inject ions 
of AZD8601
 To collect and store samples for potential explorat ion of ant i
-drug immunogenicit y. 
 Optional: To assess the effect of AZD8601 on change in digital 6 -min walk test  
(d6MWT) and maximum cont inuously walked steps (MCWS) parameter and to 
explore the relat ionship between these and echocardiographic or other parameters 
collected here in CAD pat ients (Not applicable in Germany and any other addit ional 
country  joining the study )
Note: F or details regarding exploratory  variables, measurements and analyses refer to
Secti on 5and sub sections, and 8.4.1 to 8.4.3.
3. PATIENT SELECTION, E NROLMENT, RANDOMISAT ION, 
RESTRICTIONS, DISCON TINUATION AND WITHDR AWAL 
Each patient should meet all o f the inclusio n criteria and none of the exclusio n criteria for this 
study .  Under no ci rcumstances can there be exceptions to this rule.
See Secti on 3.3for a descript ion of enrolment procedures.
3.1 Inclusion criteria
For inclusio n in the study  patients shoul d fulfil the fo llowing criteria at Visit 1 and/or 2:
1. Provisio n of signed and dated informed consent prior to any  study  specific 
procedures 
2. Males and females:
a. Mal es must be surgically sterile or using an acceptabl e method of contraception 
(see Section 3.8.5 )
b.   Fem ales m ust be of non -childbearing potential confirmed at screening by  
fulfilling one of the fo llowing cri teria a) postm enopausal  defined as amenorrhoea 

Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
30 (100)for at least 12 m onths or m ore following cessat ion of all exogenous hormonal 
treatm ents and fo llicle -stimulat ing hormone (FSH) levels in the postmenopausal 
range, b) documentation of irreversible sur gical sterilisat ion by hysterectomy, 
bilateral  oophorectomy or bilateral salpingectomy  but not tubal  ligation
3. Age >18 years
4. Indicat ion for elective CABG surgery enrolled at least 15 days before the planned 
surgery
5. Moderately reduced glo bal LVEF at rest (30% ≤ LVEF ≤ 50%) from medical 
records
6. If pat ient is on statin, ACE inhibitor/ARB, and/or beta- blocker, the dose should be 
stable at l east 2 weeks prior to Visit 1
7. Patients who are bl ood donors should not donate blood during the study  and f or 3 
months following thei r last dose of AZD8601.
3.2 Exclusion criteria
Patients shoul d not enter the study  if any of the fo llowing exclusio n criteria are fulfilled:
1. Involvement in the planning and/or conduct of the study (applies to both 
AstraZeneca staff and/or staff at t he study site)
2. Previous rando misation in the present study 
3. Parti cipation in another clinical study  with an investi gational product during the last 
3 months
4. BMI > 35 kg/m2OR poor image window for echocardiography
5. Need for CABG emergency operation. (Emergency  operati on is defined as 
significant symptom  status worsening in CAD, such as crescendo angina, unstable 
angina or ACS requiring rescheduling the revascularizat ion. CAD should be stable 
at least 3 m onths pri or to Vi sit 3.)
6. History  of ventricular arrhy thmia ( ≥ Lown III) without Implantable Cardiac 
Defibrillator (ICD)
7. History  of any clinically significant disease or disorder which, in the opinion of the 
PI, may  either put the pati ent at ri sk because of parti cipat ion in the study , or 
influence the re sults or the pati ent’s abilit y to participate in the study
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
31 (100)8. Severe co -morbidities that can interfere wit h the execut ion of the study , 
interpretati on of  study  resul ts or affect the safet y of the pat ient, in judgement of the 
investigator
9. eGFR ≤ 30 mL/min  (de rived fro m creatinine clearance, calculated by  local lab)
10.
For CFVR (Visit 1) and sMBF (Visit 2) measurement:
-Known severe adverse reactions to adenosine
-Known elevated intracranial pressure
-AV block ≥ second degree and/or sick sinus syndrome in pat ient without 
pacemaker
-Heart rate < 40 bpm (ECG verified) 
-Systolic bl ood pressure < 90 mmHg 
-Asthma or COPD with strong reactive co mponent in judgement of investigator
-Treatment with dipyridamo le (e.g. Persant in or Asasant in), theophyllamine or 
fluvoxamine that c annot be paused
11. Inabilit y to com ply wi th the protocol 
12. History  of severe allergy /hypersensi tivity or ongoing clinically important 
allergy/hypersensit ivity to drugs wi th a similar chemical structure or class as study  
drugs
13. Patients unable to give their cons ent or communicate reliably wit h the invest igator 
or vulnerable pat ients e.g., kept in detent ion, protected adults under guardianship, 
trusteeship, or committed to an inst itution by governmental  or juridical  order
14. Positive hepat itis C antibody hepat itis B virus surface ant igen or hepatit is B virus 
core anti body  or hum an immunodeficiency virus, at Visit 1
15. Known history  of drug or al coho l abuse
16. Any conco mitant m edicati ons that are known to be associated with Torsades de 
Pointes
17. History  of QT prol ongat ion associ ated wi th other medicat ions that required 
discontinuat ion of that medication
18. Congenital lo ng QT syndrome
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
32 (100)19. History  of arrhy thmia (m ultifocal premature ventricul ar contracti ons, bigeminy , 
trigeminy, ventricular tachycardia), which is symptomat ic or requ
ires treatm ent 
(CTCAE Grade 3). 
20. Current atrial fibrillat ion as well as paroxysmal atrial fibrillat ion.
Procedures for withdrawal of incorrectly  enrolled pati ents see Secti on 3.4.
3.3 Patient enrolment and randomisation
Invest igator(s) should keep a record, the patient screening log, of patients who entered pre -
study  screening. In this study , this will include all patients at the clinic scheduled for elec tive 
CABG surgery  and f or whom  the m edical  records were screened to check if they  might be 
eligible for the study .
The Investigator(s) will:
1. Obtain signed informed consent fro m the potenti al patient before any  study  specific 
procedures are performed.
2. Assig n potential pat ient a uni que enrolment number, beginning with ‘E#’.
3. Determine patient eligibilit y. See Secti on 3.1and 3.2.
4. Assign eligible pat ient unique randomisat ion code as obtained fro m call centre (see 
Secti on 3.5)
If a patient withdraws fro m participat ion in the study , then his/her enrolment/randomization 
code cannot be reused.
Randomization codes will be assigned strict ly sequent ially as pati ents beco me eligible for 
rando mizat ion.
It is estimated that 24 patients need to be randomized and receive treatment in order to achieve 
21 evaluable patients who complete safet y and tol erabili ty assessments, including 
echocardiography, at baseline and 1, 3 and 6 months fo llow up. If a patie nt withdraws 
prem aturely  (before Vi sit 7) f rom the study  they  will be replaced to achieve 7 evaluable 
patients in each treatment group. Account ing for repl acement pati ents i t is estimated that up to 
approximately  33 pati ents m ay be randomized. 
If a patien t is replaced, then a new enro lment code and randomization code will be assigned. 
The repl acement pati ent will be assigned to the same treatment as the discont inued patient 
using the next available rando mizat ion code that corresponds to the specific treatm ent.
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
33 (100)3.4 Procedures for handling incorrectly enrolled or randomized 
patients
Patients who fail to meet the eligibilit y criteria shoul d not, under any  circumstances, be 
enrolled or receive study  medicat ion.  There can be no except ions to this rule.  Patients wh o 
are enrolled, but subsequent ly found not to m eet all  the eligibilit y criteria must not be 
rando mized or init iated on treatment, and must be withdrawn from the study . If a patient i s 
withdrawn pri or to dosing, he/she will be replaced.
Where a patient does not meet all the eligibilit y criteri a but i s rando mized in error, or 
incorrectly  started on treatm ent, the Invest igator should inform the AstraZeneca study 
physician immediately, and a discussio n should occur between the AstraZeneca study 
physician and th e invest igator regarding the appropriate fo llow
-up of  the pati ent 
(discont inuat ion of IP is not an option after Visit 3). The AstraZeneca study  physician m ust 
ensure all decisio ns are appropriately documented.
3.5 Methods for assigning treatment groups
Upon completion of the randomization requirements specificat ion, the rando mizat ion will be 
produced by  Parexel  using the AstraZeneca randomizat ion solution (AZRand). The study  will 
include two dose cohorts which will receive a low or high dose of AZD8601. Dosin g for each 
dose cohort will proceed in three sent inel cohorts. In the first and second sent inel cohort 2 
patients will  be randomized to pl acebo or AZD8601 at a ratio of 1:1. In the third sent inel 
cohort 8 patients will be rando mized to placebo or AZD8601 a t a rati o of 1:3.
For each sentinel cohort an addit ional set of random numbers will be generated according to 
the sam e treatm ent allocat ion rati o. The repl acement patient will receive the lowest available 
rando mizat ion code having the same treatment allo cation.
AstraZeneca Supply  Chain will assign rando misat ion codes.
3.6 Methods for ensuring blinding
The study will have a double blind design. Placebo solut ion for inject ion will match 
appearance of AZD8601 so lution for inject ion. 
No m ember of the stu dyteam  at AstraZenec a, or representative, personnel at study centres, 
or anyclinical research organizat ion (CRO) handling data will have access to the 
rando mizat ion scheme during the conduct of the stud y, with the f ollowing except ions:
AZRand generat ing the rand omizati on scheme 
AstraZeneca Supply  Chain
The AstraZeneca or CRO personnel carrying out the labelling and packaging of 
patient specific treatments
The pharmacy personnel preparing study  drug at the si te
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
34 (100)The SRC performing safet y evaluat ion before proceedi ng wit h dosing the next 
sentinel cohort and before dose escalat ion(see 3.11.1.2 )
The DMG consist ing of internal  AstraZeneca em ployees independent of the study  
team as outlined in the combined SRC and DMG charter ,who are reviewing 
unblinded emerging safet y data and clinic al data for clinical program development 
(see3.11.1.3 )
This documentation will be kept in a secure locat ion unt il the end o f the stud y.
3.7 Methods for unblinding 
Individual treatment codes, indicat ing the treatment randomizat ion for each rando mized 
patient, will  be available to the site Invest igator(s) or pharmacists.
The treatment code should not be broken except in medical emergencies when the appropriate 
managem ent of  the pati ent requi res knowl edge of the treatment randomizat ion. The 
Invest igator documents and reports the action to AstraZeneca, without revealing the treatment 
given to patient to the AstraZeneca staff.
AstraZeneca retains the right to break the co de for SAEs that are unexpected and are 
suspected to be causally  related to an invest igational product and that potentially  require 
expedited reporting to regulatory  authori ties. Treatment codes will not be broken for the 
planned analyses of data until all decisi ons on the evaluabilit y of the data from  each individual 
patient have been m ade and docum ented.
3.8 Restrictions
Restrictions for the study  are listed in sect ions below.
AstraZeneca should be contacted if the invest igator is informed of any restrict ionviolations. 
AstraZeneca will decide whether a patient with restriction vio lation will be allowed to 
continue study  parti cipat ion.
Any restriction ment ioned below before Visit 1 and signed ICF are up to the patient upon 
inform ation given per telephone.
3.8.1 Medications restrictions
Abstain from taking any medicat ions contraindicated in the study  protocol . For the list of 
medicat ions prohibited during the study  refer to Secti on7.7.
3.8.2 Dietary restrictions
Patients shoul d fast overnight from  22:00 hours the evening before Visit 1, 2, 5, 6 and 7. 
Before Vi sit 1 and signed ICF, fasting is up to the patient upon informat ion given per 
telephone.
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
35 (100)3.8.3 Alcohol, Drugs o f abuse, Tobacco and Caffeine Restrictions
Patients shoul d:
 abstain from caffeine containing drinks for 24 hours preceding the visit s when 
adenosine infusio n is given (Visits 1, 2, 5, 6 and 7) 
 abstain from smoking for at least 1 hour prior to sMBF measure ments, or whenever 
study  procedures dem and i t. No ni cotine subst itutes will be o ffered.
 abstain from drugs of abuse during the entire study.
 abstain from alcoho l 72 hours before clinical visits
3.8.4 Exercise restrictions
Patients shoul d avoi d intensive enduranc e training (e.g. running) 48 hours before Visits 2, 5, 6 
and 7. 
3.8.5 Restrictions for male patients 
Male patients must be surgically  sterile or using an acceptable method of contraception 
(defined as barrier methods [condom or occlusive cap] in conjunct ion with spermicides) for 
the duration of the study  (from the time they  sign ICF) and for 3 m onths after administration 
of IP (AZD8601/matching placebo) to prevent pregnancy in partners.
Sperm  Donati on: Male pat ients should not donate sperm for the duration of t he study and for 
at least 3 m onths after IP administration. 
3.9 Discontinuation of investigational product
Patients m ay be di scontinued from IP in the fo llowing si tuations:
 Patient deci sion. The pati ent is at any  time free to discontinue treatment, without 
prejudice to further treatment. However, as the study  is designed so that the patient 
is administered IP on one occasion during CABG (Visit 3), it is only possible for 
the pati ent to deci de to di scont inue IP before any IP is given.
 An adverse event that, in the opinio n of the Investigator or AstraZeneca, warrants 
discontinuat ion from further dosing
 Patient noncom pliance that, in opinio n of the Investigator or sponsor, warrants 
withdrawal  (e.g. refusal  to adhere to scheduled visits)
 Risk to the patient as judg ed by the Invest igator and/or AstraZeneca.
If the patient is discont inued fro m IP (i.e. injecti ons stopped duri ng CABG), the scheduled 
study  visits, data collecti on and procedures shoul d continue according to the Clinical Study  
Protocol  (CSP) until study  closure (i .e. Vi sit 7). Alternatively , if the patient does not agree to 
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
36 (100)this opti on, a m odified foll ow up through e.g., regul ar tel ephone contacts or a contact at study  
closure shoul d be arranged, if agreed to by  the patient and in compliance with local da ta 
privacy  laws/pract ices. The approach taken should be registered in the CRF.
If pat ient is required to discont inue the IP, every  reasonable effort should be made for the 
patient to rem ain in the study  for appropri ate follow
-up.
3.9.1 Procedures for discontinua tion of a patient from investigational product 
At any time, pati ents are free to discontinue investigational product or withdraw from the 
study  (i.e., invest igational product and assessments –see Section 3.10), without prej udice to 
further treatment.  However, as the study  is designed so that the patient is administered IP on 
one occasi on during CABG (Visit 3), it is only possible for the patient to decide not to receive 
IP before any  IP is given. 
After IP has been given, the patient is st ill free to wi thdraw from  the study  (i.e. further 
assessments) although the intent ion is to keep the patient in the study  for follow-up unt il Visit 
7 has been co mpleted. If a patient is withdrawn from study , see Secti on 3.10.
3.10 Criteria for withdrawal 
3.10.1 Screen failures 
Screening failures are enrolled pat ients(i.e. signed ICF) who do not fulfil the eligibilit y 
criteria for the study , and therefore must not be randomized.  These patients should have the 
reason for study  withdrawal  recorded as ‘Screen failure’(the potential pat ient who does not 
meet one or more criteria required for participat ion in a trial, this reason for study  withdrawal 
is only  valid for not randomized patients). ‘Failure to meet randomizat ion criteria’ shoul d be 
selected for an indicat ion that the patient has been unable to fulfil/satisfy  the criteria requi red 
for assignment into a randomized group (it is only applicable for randomized studies and 
shoul d be used for pati ent wi thdrawal  post -screening). 
3.10.2 Withdrawal of the informed consent
Patients are free to withdraw from the study  at any time (invest igational product and 
assessments), without prejudice to further treatment.
A pat ient who wi thdraws consent will always be asked about the reason(s) and the presence of 
any adverse events (AE).  The Invest igator will fo llow up AEs outside of the cl inical study .  
Any mobile phone that has been provided to the patient for d6MWT and MCWS will be 
returned.
If a patient withdraws fro m participat ion in the study , then his/her enrolment/randomisat ion 
code cannot be reused. Withdrawn patients will be replac ed to achieve 7 evaluable pat ients in 
each treatment group (low dose, high dose and placebo), 21 in total. 
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
37 (100)3.10.3 Specific withdrawal criteria between visit 2 and 3
Between Visit 2 assessments at site and IP administration at visit 3, a pre -operative cardio -
thoracic surgery conference to decide dosing regimen will take place (see Section 4.1.3.1 ). If 
ident ified that the patient, according to the PET scan, has a too sm all ischemic area to 
accommodate the intended 30 inject ions the patient will not be randomized or receive IP. 
If substant ial changes of pat ient status are ident ified between visit 2 and 3, that are not 
considered to be consistent with continua tion of  the study , as judged by  the invest igator, the 
patient may  also be wi thdrawn before any IP is administered.
3.11 Discontinuation of the study
The study  may be stopped if, in the judgment of AstraZeneca, trial patients are placed at 
undue risk because o fclinically significant findings that:
 meet individual stopping criteria or are otherwise considered significant 
 are assessed as causally related to study  drug, 
 are not considered to be consistent with cont inuat ion of the study
Regardless of the reason for terminat ion, all data available for the patient at the time of 
discontinuat ion of fo llow-up m ust be recorded in the CRF. All reasons for discont inuat ion of 
treatm ent m ust be docum ented.
In terminat ing the study, the Sponsor will ensure that adequate considerat ion is given to the 
protecti on of  the pati ents’ interests.
The Sponsor reserves the right to terminate the study  at any  time. Reasons for terminat ing the 
study  may include, but are not limited to, the follo wing:
 Inabilit y to enroll sufficient pat ients into the study
 Good Clinical Pract ice (GCP) compliance issues that compromise the validit y of the 
study
 Determinat ion by the SRB or/and SRC (see Section 3.11.1 ) that the safet y of the 
patient is at ri sk 
The safet y and tol erabilit y stopping criteria take into account that each dosing group will have 
8 pati ents on IP and 4 patients on placebo (i.e., 2:1 ratio). 
Study stopping criteria 
The study  can be stopped if 4 or more patients on IP than on placebo, per dose cohort have
intolerable AEs (death or other unexpected SAEs)
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
40 (100 )Table 1 Schedule of Assessments: Enrolment and treatment periods
Screening/ 
Enrolment  Randomization CABG surgery & IP administration Notes
Visit Visit 11Visit 21Visit 3
Day -90 to -15 - 35 to -14 -1 1 2 3 4
Infor med consent x
Inclusion/exclusion 
criteriax x
Demographic data x
Medical History x x x
Concomitant 
medication x x x x x x xIncl. herbal/ nutritional
supplements
Serology x See Table 4, 5.2.1
Nicotine use x Previous and current
Height x
Weight and BMI x
FSH and LH 
samplingxFema les only, see Table 3, 
5.2.1
Randomization xAfter the pre -operative cardio -
thoracic surgery conference, 
see 4.1.3.1
IP administration x
Safety and 
tolerability:
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
41 (100 )Screening/ 
Enrolment  Randomization CABG surgery & IP administration Notes
Visit Visit 11Visit 21Visit 3
Day -90 to -15 - 35 to -14 -1 1 2 3 4
Adverse event 
review x 
(SAE only)x 
(SAE only)x 
(SAE 
only)x x x x
Blood pressure and 
pulse 
x x x x xx Supine. 
V3: 4 times/day on Days 1-3 
and at discharge on Day 4. 
Day 1: one assessment done 
pre-surgery and threepost-
surgery.
Pulse oximetry 
(saturation)
x x x xV3: 4 times/day Day 1 -4
Day 1, one assessment done 
pre-surgery and three post-
surgery.
See 5.2.4.1
dECG with digital 
source file
x x x x x x xV3: Once Day -1 as baseline, 2 
times/day Day 1 -4. Day 1 both 
timepoints will be post -
surgery.
See 5.2.3
Telemetry 
xStart on Day -1, pause during 
CABG, re -start post -surger y 
and continue until discharge. 
See 5.2.3
Physical 
examinationx (brief) x xSee 5.2.2
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
44 (100 )Screening/ 
Enrolment  Randomization CABG surgery & IP administration Notes
Visit Visit 11Visit 21Visit 3
Day -90 to -15 - 35 to -14 -1 1 2 3 4
Plasma samples for 
VEGF -A protein 
analysis to be 
stored in biobank x x x x x xV2: 2 samples with at least 15 
min in between.
V3: Pre-surgery Day -1. Post -
surgery 3, 6, 24, 34, 48 and 72 
h after first epicardial 
injection.2
See 5.7
Plasma samples for 
future exploratory 
analysis of 
AZD8601 (VEGF 
modRNA) to be 
stored in biobankx x xPre-surgery Day -1. Post -
surgery 1, 3 and 48 h after first 
epicardial injection.2
Plasma samples to 
be stored in 
biobank for 
potential 
exploration of anti -
drug 
immunogenicity xSee 5.7
Plasma samples to 
be stored in 
biobank for 
potential 
exploratory 
analysesxx  x xSee 5.7
V3: 6, 48 and 72 hours after 
first epicardial injection.2
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
45 (100 )1Visit 1 and Visit 2 can be combined, however PET and CFVR (if applicable) assessments should be done on separate days see 4.1.3
2Post-surgery  samples should be taken as close to the specified timepoint as possible, but a time window of ± 1 hour is allowed.
Table 2 Schedule of assessments: Follow -up period
Follow-up Notes
Visit Visit 4 (TC) Visit 5 Visit 6 Visit 7
Day/month (time 
window)14 
(±2 days)1 month 
(±3 days)3 months
(±14 days)6 months
(±14 days)
Concomitant 
medication x x xIncl herbal/ nutritional 
supplements
Safety and 
tolerability:
Adverse event 
review x x x x
Blood pressure and 
pulse x x xSupine. See 5.2.4.1
dECG with digital 
source filex x xSee 5.2.3
Physical 
examinationx x (brief) x (brief)See 5.2.2
Blood and urine 
samples for safety 
laboratory 
evaluations x x xSee 5.2.1
Exploratory 
Assessm ents
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
47 (100 )Follow-up Notes
Visit Visit 4 (TC) Visit 5 Visit 6 Visit 7
Day/month (time 
window)14 
(±2 days)1 month 
(±3 days)3 months
(±14 days)6 months
(±14 days)
Plasma samples for 
VEGF -A protein 
analysis xSee 5.7
Plasma samples to 
be stored in biobank 
for potential 
exploration of anti -
drug 
immunogenicity x x xSee 5.7
Plasma samples to 
be stored in biobank 
for potential 
exploratory 
analysesx x xSee 5.7
Order of assessments : 
NB: not all assessments are applicable for all visits but this is the order when they are done:
1.PRO (KCCQ, SAQ) and NYHA classificat ion
2.Supervised d6MWT
3.ECG, AE -revie w, physical examinat ion, vital signs (BP, pulse, pulse oximetry )
4.Safetylaboratory  sampling, sam ples f or VEGF, for AZD8601, for hsTnT and NT- proBNP, for anti -drug immunogenicit y 
and for biobanking
5. Echo, 
6.15O PET/CT angiogram
7.Post-surgery  blood sam ples

Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
49 (100)Patients who fulfil all o f the inclusio n criteria and none of the exclusio n criteria will be 
rando mized at this visit.
The patient will be fast ing on arrival to the clinic.
Baseline assessments of rest and stress MBF by 15O PET will be done. Patients will undergo 
a 15O PET and con trast-enhanced CT scan to generate a combined CT -angiogra m and cardiac 
perfusio n map. 
Patients will  be invi ted to parti cipate in the opti onal AZ Activi ty App com ponent of the study . 
During this visit patients will be provided with a mobile phone (unless they  have a sui table 
iPhone already) and given access to a mobile so ftware applicat ion (app) that will be used to 
conduct the d6MWT and MCWS. The app will be activated on -site at vi sit 2 and a supervised 
d6MWT will take place. For further informat ion see Section 5.3.6 . (N/A in Germany and any 
other addit ional country  joining the study .)
Randomization will take place after the outcome of the pre -operative cardio -thoraci c surgery  
conference is available, as de scribed in 4.1.3.1 . This should optimally occur latest Day  -10, 
however, this t imeframe can be reduced if delivery of invest igational product to the site can be 
warranted before the planned date of CABG.
Further assessments during Visit 2 are outlined in Table 1.
4.1.3.1 Pre-operative cardio
-thoracic surgery conference to decide individual injection 
map
Based on quant itative coronary  angi ogram  and PET/CT perfusio n map available fro m Visit 2, 
consensus will be reached regarding surgical procedure individualized for each pat ient. Based 
on the i schemic area ( regions with sMBF < 2.3±0.3 mL/g/min or < 80±10% of the segment 
with highest sMBF) identified on PET scan and coronary  artery  morphol ogy by CT-
angiogram, a tailor -made injection map of approximately 1 cm inter- site distance wi th 30 
epicardial injections wi ll be determined to guide the inject ion procedure during CABG to 
target the ischemic but viable (rest perfusio n > 60% of normal myocardium rest ing flow of 1 
mL/g/min) myocardium. 
Treatment will be focused on the LCA territory , starting wi th the l argest i schemic area, i .e. 
either left anteri or descending LAD or LCX supply  terri tory. If the number of inject ions 
remaining after complete treatment of the first largest ischemic area is not sufficient to treat 
the second one as ident ified by the inject ion map, t he area will be partially treated applying 
the sam e inject ion distance.
The individualized inject ion map will be determined by an expert committee of study site staff 
involved in the study , where the following are mandatory :
Responsible thoracic surgeon, P ET phy sician and cardi ologist at the l ocal site
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
50 (100)PET core l ab responsible and at least one more thoracic surgeon from another hospital 
Prior to the meeting, the interpretation of the PET scan will be agreed with the core lab 
responsible person.
If ident ified that the patient, according to the PET scan, has a too small ischemic area to 
accommodate the intended 30 inject ions the patient will not be randomized or receive IP.
4.2 Treatment period
4.2.1 Visit 3 –CABG surgery and IP administration (Day -1 to Day 4
)
At Visit 3, the patient will co me to the clinic and undergo assessments as outlined in Table 1. 
During the operation, fo llowing by -pass graft ing immediately before reperfusio n, pati ents will 
receive 30 epicardial inject ions of the treatment they  have been rando mized to: placebo or any 
of two different doses of AZD8601 (see Section 7.2). The inject ions will be given under 
cardi oplegia into all accessible ischemic border zones according to the individualized inject ion 
map agreed beforehand (see 4.1.3.1 ). The actual inject ion procedure will be documented by  
filming/taking photo during this part of the surgery. After surgery , the surgeon will document 
in the medical records and mark with a pe n on a print -
out of the injection map where the 
actual inject ions were placed. Further details will be provided in a separate Manual o f 
Procedures (MoP). 
Patients will  be requi red to rem ain hospi talized at the study  site hospi tal approximately  4 days 
post-surgery  for safet y and tol erabilit y evaluat ion with extensive mo nitoring in line with 
norm al clinical routine.
Significant pericardial  effusi on will be excluded by  assessment of hemoperi cardium  and/or 
tamponade using bed- side echocardi ography  and assessme nt of maximum thickness of 
pericardial  fluid before discharge from the hospital.
4.3 Follow -up period
4.3.1 Visit 4 -Telephone contact follow -up (Day 14 ±2 days) 
Two weeks after the operation, the investigator or research nurse will make a phone call to the 
patient to follow -up on adverse events.
4.3.2 Visit 5 –Follow -up (1 month ±3 days)
The patient will be fast ing on arrival to the clinic.
During this visit, rest and stress 15O PET perfusio n scan will be performed, and also 
echocardiography including assessment of pericardium, regional/glo bal cardiac functi on and 
cardi ac vol umes. If the 15O PET is not available at the hospital where the patient is enrolled , 
the pati ent will be referred to another hospital for this assessment onl y; however, the CT scan 
may also be performed at the si te of the 15O PET scan if required.
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
51 (100)Before the 15O PET assessment it should be verified that the patient does not have:
- Heart rate < 40 bpm (ECG verified) 
- Systolic bl ood pressure < 90 mmHg
For other assessments, refer to Table 2.
4.3.3 Visit 6 –Follow up (3 months ±14 days)
The patient will be fast ing on arrival to the clinic.
A CT angiogram will be performed after PET studies. All ot her assessments will be ident ical 
to Visit 5. If the 15O PET is not available at the hospital where the patient is enrolled , the 
patient will be referred to another hospital for this assessment only; however t he CT scan may 
also be performed at the site of the 15O PET scan if required.
4.3.4 Visit 7 –Final follow -up (6 months ±14 days)
The patient will be fast ing on arrival to the clinic.
Echocardi ography , incl uding stress cardi ac function, regi onal/gl obal cardi ac funct ion and 
cardi ac vol umes will be performed. 
Before the stress echocardiography/LAD CFVR assessment it shoul d be verified that the 
 
Any mobile phone that has been provided to the patient for d6MWT and MCW S will  be 
returned.
For other assessments, refer to Table 2, Secti on 4.
5. STUDY ASSESSMENTS
The Rave Web Based Data Capture (WBDC) system will be used for data collect ion and 
query  handling.  The investigator will ensure that data are recorded on the electroni cCase 
Report F orms (eCRF) as specified in the Clinical Study  Protocol  and in accordance with the 
instructi ons provi ded.
The invest igator ensures the accuracy, completeness, and timeliness of the data recorded and 
of the provisio n of answers to data queries according to the Clinical Study  Agreement. The 
investigator will sign the completed eCRF.  A copy o f the com pleted eCRF will be archived at 
the study  site.

Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
52 (100)5.1 Efficacy assessments (NA)
Efficacy is only  evaluated in an exploratory  fashion is this study .
5.2 Safet y assessments
5.2.1 Laboratory safety assessments
Blood and urine samples for determinat ion of clinical chemistry , haematol ogy, coagulati on, 
and urinalysis will be taken at the times indicated in Table 1and Table 2, Secti on 4.
The clinical chemistry , haematol ogy and urinalysis will be performed at a local laboratory  at 
or near to the Invest igator site.  Sample tubes and sample sizes may vary depending on 
laboratory  method used and routine practice at the si te. AstraZeneca will provide the same 
type of urine dipst ick test kit to all sites.
The l aboratory  variables given in Table 3and Table 4below will be measured.
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
53 (100)Table 3 Standard Clinical Laboratory Evaluation Panels
Hematology/Hemostasis (whole blood) Clinical Chemistry* (serum or plasma)
White blood cell (WBC) count Sodium
Red blood cell (RBC) count Potassium
Hemoglobin (Hb) Urea
Hematocrit (HCT) Creatinine
Mean corpuscular volume (MCV) Albumin
Mean corpuscular hemoglobin (MCH) Calcium
Mean corpuscular hemoglobin concentration 
(MCHC)Phosphate
Neutrophils absolute count Alkaline phosphatase (ALP) “LIVER PANEL”
Lymphocytes absolute count Alanine aminotransferase (ALT) “LIVER 
PANEL”
Monocytes absolute count Aspartate aminotransferase (AST) “LIVER 
PANEL”
Eosinophils absolute count Total bilirubin “LIVER PANEL”
Basophils absolute count FSH (females only, at screening)
Platelets LH (females only, at screening)
Reticulocytes absolute count Urinalysis 
Coagulation Glucose (dipstick)
International normalized ratio (INR) Albumine (quantification/semi -quantification)
Activated partial thrombin time (APTT) Protein (dipstick)
Fibrinogen Blood (dipstick)
WBC (leukocytes) (dipstick)
Creatinine (quantification)
Table 4 Other Clinical Safety Panels
Panel Name Markers
Serology (screening only) Hum an immunodeficiency virus (HIV) I and II 
Hepatitis B surface Antigen (HBsAg)
Hepatitis C virus antibody
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
54 (100)Addit ional safet y samples may  be collected if clinically indicated at the discret ion of the 
Invest igator.  The date, time of collection and results (values, units and reference ranges) will 
be recorded on the appropriate eCRF.
The Investigator should make an assessment of the available re sults wi th regard to clinically 
relevant abnorm alities.  The l aboratory  resul ts shoul d be si gned and dated and retained at 
centre as source data for laboratory  variables.  For informat ion on how AEs based on 
laboratory  tests shoul d be recorded and reported , see Section 6.3.
NB. In case a patient shows an AST orALT ≥3xULN ortotal bilirubin ≥2xULN please refer 
to Appendix C‘Actions required in cases o f combined increase o f Aminotransferase and Total 
Bilirubin –Hy’s Law’, for further instructions.
5.2.2 Physical examination
A co mplete ph ysical examinat ion will be performed at Visits 2, 3 and 5 and include an 
assessment of the fo llowing: general  appearance , respiratory , cardi ovascular, abdomen skin, 
head and neck (including ears, ey es, nose and throat), lymph nodes, thy roid, abdo men, 
muscu lo-skeletal  (including spine and extremit ies) and neurological systems. 
At Visits 1, 6 and 7 a brief physical  examinat ion will  be perform ed (general  appearance, skin, 
abdo men and m uscul oskeletal , cardi ovascular and respiratory  system s).
For handling of AE s based on examinat ions and tests see Section 6.3.6
5.2.3 ECG
12-lead ECG recordings will be collected using provided ECG machines according to the 
assessments schedule, see Table 1and Table 2, Secti on 4using. On Day 1, Visit 3, the two 
ECG measurements should be done post -surgery  with reasonable time interval. The 
investigator will make an overall evaluat ion of the ECG as normal or abnormal. If abnormal, it 
will be decided whether or not the abnormalit yis clinically  significant or not clinically 
significant and the reason for the abnormalit y will be recorded on the eCRF. Digital ECGs in 
Table 1and Table 2refers to the storage of digital Safet y ECG source files that are retrievable 
for adjudicat ion if required, e.g. for off -line analysis by  experienced ECG readers.
Abnorm al values shall  not be recorded as AEs unless deemed clinically  significant. The 
printout of the ECG is to be signed, dated and filed in the ISF along wit h a signed and dated 
copy  (if the printouts are not on archive -qualit y paper ).
To ensure robust data to evaluate and confirm potent ia
l outliers in the coming increased 
cardi ovascular risk population, the requirement is to use digitally stored 12- lead Safet y ECGs 
where the digital source file is available for analysis. Telemetry  online ECG surveillance for 
rhythm mo nitoring and arrhy thmia detection will be done at the given time points. Telemetry  
will be init iated the day  before operati on when the patient arrives to the hospital ward and 
continue until the patient is mo ved to the op erating room (interruptions may be necessary for 
clinical routines and other study  assessments). That will provide collect ion of so me pre-
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
55 (100)operative baseline rhyt hm and heart rate monitoring (preferably  at least 6 hours of total 
durati on of  pre-operative te lemetry  but will  depend on clinical routines). It will then be re -
started when the patient comes back to the ward after the operation and cont inue as long as the 
patient stays at the ward (approximately  4 days post -operatively). Arrhyt hmia episodes will be
visually confirmed by  the attending physician and printed and if possible stored digitally for 
potenti al over read by  cardi ologist. If si te has the capabilit y to store telemetry  data di gitally, 
this shoul d be done.
The fo llowing param eters or time interva ls will be recorded for each ECG: RR, PR, QRS, QT, 
QTcF and heart rate (HR). A summary of clinically relevant ECG findings fro m 12-lead ECGs 
and observed arrhyt hmias during telemetry  will be presented and discussed at the SRB/SRC 
meet ings (see Sect ion 3.11.1 )
5.2.4 Vital signs
Vital signs will  include pulse, and systolic and diastolic blood pressure. Vital signs will be 
obtained at time points indicated in Table 1(and ad -hoc as medically indicated).
For handling of AEs based on examinat ions and tests see Section 6.3.6
5.2.4.1 Pulse, pulse oximetry and blood pressure
Pulse (beats/minute, radial artery , during 30 seconds) and pulse oximetry  will be m easured 
before blood pressure and in a lying posit ion after 10 minutes of rest. Thereafter, systolic and 
diastolic blood pressure (mmHg, the cuff method on the arm opposite to the one used for 
blood sampling) will  be measured using the same cuff, appropriate for arm circumference, and 
in the same position, through out the study . Pati ents shoul d be in the same position for the vital 
signs m easurements throughout the study .
Measurements will be done at the time points indicated in see Table 1and Table 2, Secti on 4.
5.2.5 Other safety assessments
5.2.5.1 Hemopericardium and/or tamponade assessment with echocardiography
Hem operi cardium  and/or tam ponade will  be assessed by  clinical routine echocardiography  
evaluat ion to assess any  postoperative peri cardial effusi on at Vi sit 3, day  3 or 4 post CABG.
5.3 Other assessments
A number of exploratory  assessments will be performed in the study  as described below.
5.3.1 15O PET and CT angiogram
Prior to CABG, each pat ient will undergo a dynamic oxygen -15 labelled water positron 
emissio n tom ography  (15O PET)/CT scan, which generates a combined image of coronary  
angiogram superimposed on a my ocardial  perfusion map to l ocate areas of my ocardial  
ischemia and dysfunct ion.
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
57 (100)The PROs in the study  are:  Kansas Cit y Cardi omyopathy  Quest ionnaire (KCCQ) and Seattl e 
Angina Quest ionnaire (SAQ). 
The PRO questionnaires used in this study will all be collected by paper, subject -self completed and do 
not require training. Site personnel or designated data management staff should enter the responses in 
the appropr iate sections of the Case Report Form. The total time estimated to complete the 
questionnaires at the clinic visit is approximately 20 min. The quest ionnaires to be used are 
further described in Sect ion 5.3.4.1 and 5.3.4.2 .
The time points for the below listed PRO assessments are given in Table 1and Table 2, 
Secti on 4.
PRO questionnaires should be co mpleted by  the pati ent in private. Appo inted site staff should 
remind patients that there are no right or wrong answers and avo id clarifying items in order to 
avoid bias.
Patients m ust not receive help from relat ives, friends, or clinic staff to answer the PRO 
questionnaires. If a patient uses visual aids (e.g., spectacles or contact lenses) for reading and 
does not have them when he attends the clinic, the patient will be exempted from co mpleting 
the PROs.
The patient should be given sufficient time to complete the PRO questionnaires at his/her own 
speed. Appo inted site staff m ust m onitor com pliance to ensure all data is captured.
5.3.4.1 Kansas City Cardiomyopathy Questionnaire 
The KCCQ is a sensit ive, specific, and responsive healt h
-related qualit y of life measure for 
heart failure. It is a 23 -item, self -administered instrument that quantifies physical funct ion, 
symptoms (frequency , severi ty and recent change), social funct ion, self -efficacy  and 
knowl edge, and qualit y of life.
In the KCCQ, an overall summary score can be derived from the physical func tion, symptom  
(frequency and severit y), soci al functi on and qualit y of life do mains. For each domain, the 
validit y, reproducibilit y, responsiveness and interpretabilit y have been independent ly 
established. Scores are transformed to a range of 0 -100, in whi ch higher scores reflect better 
healt h status. 
The m aster versi on is encl osed in Appendix D.
5.3.4.2 Seattle Angina Questionnaire
The Seattle Angina Quest ionnaire is a sensit ive, specific, and responsive healt h -related qualit y 
of life instrument for coronary  artery  disease.
The SAQ is a self -administered, disease -specific measure for patients with CAD that is valid, 
reproducible, and sensit ive to clinical chan ge. 
The SAQ quant ifies patients’ physical limitat ions caused by angina, the frequency o f and 
recent changes in their symptoms, their sat isfaction with treatm ent, and the degree to which 
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
59 (100)5.5 Pharmacodynamics 
For samples taken for analysis of exploratory  biomarkers, see Section 5.7. No other 
pharmacodynamics (PD) samples will be taken.
5.6 Genetics
In thi s study , no genet ics samples will be co llected. 
5.7 Biomarker analysis 
The patient’s consent to the use of donated bio logical  samples is m andatory  to be able to 
participate in the study .  
Biological samples (e.g., blood samples) will be collected for analysis of exploratory biomarkers to 
assess correlations with disease activity, effects of AZD8601, clinical outcomes and toxicity. This 
includes VEGF -A downstream biomarkers. As outlined in Table 5, some exp loratory biomarkers will 
be analysed and reported within this study and others may potentially be analysed.  For exploratory 
biomarkers that might be analysed, results will be presented outside the CSR. Samples will be 
collected at the visits and time poin ts listed in Table 1and Table 2. Post -surgery samples at Visit 3 
should be taken as close to the specified timepoint as possible, but a time window of ± 1 hour is 
allowed.
Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
60 (100 )Table 5 Exploratory biomarkers
Panel Name Biomarkers Analyses
Cardiovascular biomarkers  (change from baseline 6 
months post CABG)Analysis will be performed as part of the study 
and done at a local laboratory at or near to the 
Investigator site. 
Sample tubes and sample volumes may vary 
depending on laboratory method used and routin e 
practice at the site.
VEGF -A protein Venous blood samples for the determination of 
plasma concentrations of VEGF -A proteinAnalysis will be performed as part of the study. 
Samples to be handled by a central laboratory 
will be collected, labelled store d and shipped as 
detailed in the Laboratory Manual. Samples from 
patients treated with either AZD8601 or placebo 
will be analysed for VEGF -A protein.
Samples will be collected at the time points given 
in Table 1and Table 2Section 4.
Potential exploratory analysis of plasma 
concentrations of AZD8601 (VEGF -A modRNA)Samples will be collected for potential future 
analysisAny data from these potential analyses will be 
presented outside the CSR.
Samples to be handled by a central laboratory 
will be collected, labelled stored and shipped as 
detailed in the Laboratory Manual.
Plasma samples will potentially be analysed for 
VEGF -A concentrations, by a qualified vendor on Potential exploratory biomarker research Samples will be collected for potential 
exploratory research aimed at investigating 
biomarkers including VEGF -A downstream 
biomarkers involved in PK, PD, efficacy, safety 
and tolerabilit y related to AZD8601 treatment

Clinical Study Protocol
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
61 (100 )Panel Name Biomarkers Analyses
Potential Analysis of Anti -drug Immunogenicity Samples for potential analysis of anti -drug 
immunogenicity will be collected.behalf of AstraZeneca Research and 
Development (R&D), using an assay that has 
been validated to fit the exploratory purpose of 
the study.
Samples will be collected at the time points given 
in Table 1and Table 2Section 4.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
62 (100)Full details o f the analy tical method and analyses performed will be described in a separate 
Bioanaly tical Report. 
All samples st ill within the known stabilit y of the analy tes of  interest (i .e. VEGF -A) at the 
time of receipt by  the analy tical laboratory  will be analysed.
5.7.1 Storage, re -use and destruction of biological samples
Samples will  be stored for a m aximum  of 15 y ears fro m the date of the Last Patient’s Last 
Visit, after whi ch they will be destroy ed.  The results of this bio marker research will be 
reported either in the CSR itself or as an addendum, or separately in a scient ific report or 
publicat ion. The results of this bio marker research may be pooled wit h bio marker data from 
other studi es wi th the study  drug to generate hy potheses to be tested in fut ure research.
5.7.2 Labelling and shipment of biological samples
The Principal Invest igator ensures that samples are labelled and shipped in accordance with 
the Laboratory  Manual and the Bio logical Substance, Category  B Regulati ons (m aterials 
containing or suspe cted to contain infect ious substances that do not meet Category  A cri teria), 
see Appendix B‘IATA 6.2 Guidance Document’.
Any samples ident ified as Infect ious Category  A materi als are not shipped and no further 
samples will be taken from the patient unless agreed with AstraZeneca an d appropri ate 
labelling, shipment and containment provisio ns are approved.
5.7.3 Chain of custody of biological samples 
A full chain o f custody  is maintained for all samples throughout their lifecycle.
The Principal Invest igator at each centre keeps full traceabilit y of co llected bio logical  samples 
from the pati ents while in storage at the centre until shipment or disposal (where appropriate) 
and keeps documentation of receipt of arrival.
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps documentation of receipt of arrival.
AstraZeneca keeps oversight of the ent ire life cycle through internal procedures, monitoring o f 
study  sites and audi ting of  external  laboratory  providers.
Samples retained for further use are registered in the AstraZeneca designated Biobank during 
the ent ire life cycle.
5.7.4 Withdrawal of Informed Consent for donated biological samples 
If a patient withdraws consent to the use of donated bio logical samples, the sam ples will  be 
disposed of/destroy ed, and the acti on documented.  If samples are already  analysed ,
AstraZeneca is not obliged to destroy  the resul ts of this research.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
63 (100)As collect ion of the bio logical samples is an integral part of the study , then the pati ent is 
withdrawn from  further study  parti cipat ion.
The Principal Invest igator:
 Ensures pat ients’ withdrawal of informed consent to the use of donated samples is 
notified immediately to AstraZeneca
 Ensures that bio logical samples from th at patient, if stored at the study  site, are 
immediately  identified, disposed of /destroy ed, and the action documented
 Ensures the organizat ion(s) ho lding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of/ destroy ed, the 
action docum ented and the signed document returned to the study  site
 Ensures that the patient and AstraZeneca are informed about the sample disposal.
AstraZeneca ensures the organizat ions holding the samples is/are informed about the 
withdrawn consent immediately and that samples are disposed of/destroy ed and the act ion 
docum ented and returned to the study  site.
6. SAFETY REPORTING AND MEDICAL MANAGEMENT
The Principal Invest igator is responsible for ensuring that all staff invo lved in the study  are 
familiar wit h the content of this sect ion.
6.1 Definition of adverse events
An adverse event is the development of any untoward medical occurrence in a pat ient or 
clinical study  patient administered a medicinal product and which does not necessarily  have a
causal relat ionship with this treatm ent.   An AE can therefore be any unfavourable and 
unintended sign (e.g. an abnormal laboratory  finding), symptom (for example nausea, chest 
pain), or disease temporally associated with the use of a medicinal product, w hether or not 
considered related to the medicinal product. 
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may  occur at any  time, including 
run-in or washout perio ds, even if no study  treatm ent has been administered.
6.2 Definitions of serious adverse event
A serious adverse event is an AE occurring during any study  phase (i .e., run -in, treatment, 
washout, follow -up), that fulfils one or more of the fo llowing cri teria:
 Results in death
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
64 (100) Is immediately life -threatening
 Requi res in -patient hospi talisat ion or prolongat ion of exist ing hospi talisat ion 
 Results in persistent or significant disabilit y or incapaci ty. 
 Is a congenital abnormalit y or birth defect
 Is an important medical event that may jeopardise the patient or may require 
medical intervention to prevent one of the outcomes listed above.
For further guidance on the definit ion of a SAE, see Appendix Ato the Clinical Study  
Protocol .
6.3 Recording of adverse events
6.3.1 Time period for collection of adverse events
Adverse Events will be co llected fro m Visit 3 (CABG surgery )throughout the treatment 
period and including the fo llow-up peri od (until  Visit 7).
SAEs will be recorded from the time of informed consent (Visit 1).
6.3.2 Follow -up of unresolved adverse events
Any AEs that are unresolved at Visit 6 in the study are fo llowed up by  the 
Invest igator for as long as medically indicated, but without further recording in 
the CRF. AstraZeneca retains the right to request addit ional inform ation for any  
patient wi th ongoing AE(s)/SAE(s) at the end of the study , if judged necessary .
6.3.3 Variables 
The fo llowing vari ables will be collected for each AE;
 AE (verbat im)
 The date and time when the AE started and stopped
 Maximum intensit y 
 Whether the AE is serious or not
 Invest igator causalit y rating against the Investigat ional Product (yes or no)
 Action taken with regard to invest igational product
 Whether the AE caused patient’s withdrawal fro m study  (yes or no )
 Outcom e
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
65 (100)In addit ion, the fo llowing vari ables will be collected for SAEs:
 Date AE m et cri teria for seri ous AE
 Date Invest igator became aware of serious AE
 AE is serious due to
 Date of hospitalisat ion
 Date of discharge
 Probable cause of death
 Date of death
 Autopsy  performed
 Causalit y assessment in relat ion to Study  procedure(s)
 Causalit y assessment to other medicat ion
 Causalit y assessment to drug injection procedure
 Descript ion of AE
It is important to dist inguish between serious and severe AEs.  Severit y is a measure of 
intensity whereas seri ousness is defined by the criteria in Sect ion 6.2.  An AE of severe 
intensity need not necessarily be considered serious.  For example, nausea that persists for 
several hours may  be consi dered severe nausea, but not a SAE unless it meets the criteria 
shown in Section 6.2. On the other hand, a stroke that results in only  a limi ted degree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies t he criteria 
shown in Section 6.2.
6.3.4 Causality collection
The Investigator will assess causal relat ionship between Invest igational Product and each 
Adverse Event, and answer ‘yes’ or ‘no’ to the question ‘Do y ou consi der that there is a 
reasonable possibilit y that the event m ay have been caused by  the investi gational product?’
For SAEs causal relationship will also be assessed for other medicat ion and st udy procedures, 
such as drug injection procedure. Note that for SAEs that could be associated with any study  
procedure the causal relat ionship is implied as ‘yes’.
A guide to the interpretation of the causalit y quest ion is found in Appendix Ato the Clinical 
Study  Protocol .
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
66 (100)6.3.5 Adverse events based on signs and symptoms
All AEs spontaneously reported by  the pati ent or reported in response to the open questi on 
from the study  site staff: ‘Have y ou had any heal th probl ems since the previous visit/y ou were 
last asked?’ , or revealed by observat ion will  be collected and recorded in the CRF. When 
collect ing AEs, the recording of diagnoses is preferred (when possibl e) to recording a list of 
signs and symptoms.  However, if a diagnosis is known and there are other signs or symptoms 
that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be 
recorded separately.
6.3.6 Adverse events based on examinations and tests
The results from the Clinical Study  Protocol  mandated l aboratory  tests and vi tal signs will be 
summarised in the CSR.  Deterioration as compared to baseline in protocol -mandated 
variables should therefore only  be reported as AEs if t hey fulfil any  of the SAE cri teria or are 
the reason for discont inuat ion of treatment with the invest igational product.
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported a s an AE and the associated laboratory result/vital sign 
will be considered as addit ional informat ion.  Wherever possible the reporting Invest igator 
uses the clinical, rather than the laboratory  term  (e.g., anaemia versus low haemoglobin 
value). In the abse nce of clinical signs or symptoms, clinically relevant deteriorations in non -
mandated parameters should be reported as AE(s).
Deteri oration of  a laboratory  value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or aggravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE
6.3.7 Hy’s Law
Cases where a patient shows elevat ions in liver bio chemistry  may require further evaluat ion
and occurrences o f AST or ALT ≥ 3xULN together with total bilirubin ≥ 2xULN may need to 
be reported as SAEs. Please refer to Appendix Cfor further i nstructi on on cases of increases 
in liver bio chemistry  and evaluat ion of Hy’s Law.
6.4 Reporting of serious adverse events
All SAEs have to be reported, whether or not considered causally related to the invest igational 
product, or to the study  procedure(s). Al l SAEs will be recorded in the CRF.
If any SAE occurs in the course of the study, then Invest igators or other site personnel inform 
the appropriate AstraZeneca representatives within one day  i.e., immediately  but no later 
than 24 hours of when he or she beco mes aware of it.
The designated AstraZeneca representative works with the Invest igator to ensure that all the 
necessary  informat ion is provided to the AstraZeneca Patient Safet y data entry  site within 1
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
67 (100)calendar day of initial receipt for fatal and life threatening events and within 5 calendar
days of initial receipt for all other SAEs.
For fatal  or life -threatening adverse events where important or relevant informat ion is missing, 
active fo llow
-up is undertaken immediately .  Investi gators or other site personnel inform 
AstraZeneca representatives of any  follow-up informat ion on a previously  reported SAE 
within one calendar day  i.e., immediately but no later than 24 hours of when he or she 
beco mes aware of it.
Once the Invest igators or other site personne l indicate an AE is serious in the WBDC system, 
an autom ated email alert is sent to the designated AstraZeneca representative.
If the WBDC system is not available, then the Investigator or other study  site staff reports a 
SAE to the appropriate AstraZeneca representative by  fax (+46 31 776 37 34) or e -mail 
AEMailbo xWBDCTCS@astrazeneca.co m.
The AstraZeneca representative will advise the Investigator/study  site staff how to proceed. 
The reference document for definit ion of expectedness/listedness is the IB for the AstraZeneca 
drug.
6.5 Overdose
An overdose is defined as a pat ient receiving a dose of AZD8601 in excess of that specified in 
this protocol . No specific treatm ent is recommended for an overdose. The Invest igator will use 
clinical judgement to treat any overdose.
 An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE m odules in the CRF and on the Overdose CRF module.
 An overdose without associated symptoms is only  reported on the Overdose CRF 
module.
If an overdose on an AstraZeneca study  drug occurs in the course of the study , then the 
Invest igator or other site personnel inform appropriate AstraZeneca representatives 
immediately , or no later than 24 hours of when he or she beco mes aware of it.
The designated AstraZen eca representative works with the Invest igator to ensure that all 
relevant informat ion is provided to the AstraZeneca Patient Safet y data entry  site.
For overdoses associated with a SAE, the standard reporting t imelines apply, see Sect ion 6.4.  
For other overdoses, reporting must occur within 30 day s.
6.6 Pregnancy
All pregnancies and outcomes of pregnancy should be reported to AstraZeneca except for:
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
68 (100)If the pregnancy  is discovered be fore the study  patient has received any  study  drug
6.6.1 Maternal exposure
Women of childbearing potential are not allowed to be included in this study . Shoul d a 
pregnancy st ill occur before Visit 3, the patient will be withdrawn fro m the study  and will  not 
receive IP. Should a pregnancy occur after Visit 3, the fo llow
-up assessments will be 
perform ed as planned until Visit 7, with the exceptio n of PET and CT which will be omitted 
due to radiat ion. The pregnancy shall be reported to AstraZeneca.
Pregnancy itself is not regarded as an adverse event unless there is a suspicio n that the IP 
under study  may have interfered with the effect iveness of a contraceptive medication.  
Congenital abnormalit ies/birth defects and spontaneous miscarriages should be reported and 
handled as SAEs.  Elect ive abortions without complicat ions should not be handled as AEs.   
The outcome o f all pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic 
pregnancy, normal birth or congenital abnormalit y) should be fo llowed up and docu mented 
even if the patient was discont inued from the study.
If any pregnancy  occurs in the course of the study , then the Invest igator or other site personnel 
informs the appropriate AstraZeneca representatives within 1day  i.e., immediately but no 
later than 24 hours of when he or she becom es aware of i t.
The designated AstraZeneca representative works with the Invest igator to ensure that all 
relevant informat ion is provided to the AstraZeneca Patient Safet y data entry  site wi thin 1 or 5 
calendar day s for SA Es (see Secti on 6.4) and wi thin 30 days for all other pregnancies.
The same timelines apply when outcome informat ion is available.
In case of pregn ancy, the pregnancy  data and the outcom e of the pregnancy  will be collected.
6.6.2 Paternal exposure 
As a precaution, all male pat ients should avo id fathering a child by eit her true abst inence or 
the use of two effect ive means o f contraception with their partne r from the time of IP 
administration unt il 3 months after the last dose of IP. Should a partner, despite precautions, 
beco me pregnant during this period it should be reported in the same manner as described in 
Secti on 6.6.1 if the partner consents to this.
Sperm  donati on
Male patients should not donate sperm for the duration of the study  and f or at l east 3 m onths 
after the l ast day  of IP administration.
6.7 Medication Error
For the purposes of this clinical study  a medicat ion error is an unintended failure or mistake in 
the treatment process for an AstraZeneca study  drug that ei ther causes harm to the patient or 
has the potential to cause harm to the patient. 
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
69 (100)A medicat ion error is not l ack of efficacy  of the drug, but rather a human or process related 
failure while the drug is in control of the study  site staff or pati ent.
Medicat ion error includes situat ions where an error. 
occurred
was i dentified and intercepted before the patient received the drug
did not occur, but circumstances were recognize that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name confusio n
Dispensing error e.g. medicat ion prepared incorrectly , even if i t was not actually  given to 
the pati ent
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated e.g. tablet disso lved in water when it should be taken as a solid 
tablet 
Drug not s tored as instructed e.g. kept in the fridge when it should be at room temperature 
Wrong patient received the medication 
Wrong drug administered to patient
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Accident al overdose (will be captured as an overdose)
Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open l abel studi es, even if an AZ product 
Medicat ion errors are not regarded as AEs but AEs may  occur as a consequence of t he 
medicat ion error.  
If a medicat ion error occurs in the course of the study , then the Invest igator or other site 
personnel informs the appropriate AstraZeneca representatives within 1 day i.e., immediately 
but no later than 24 hours of when he or she be comes aware of i t.
The designated AstraZeneca representative works with the Invest igator to ensure that all 
relevant informat ion is completed wi thin 1 or 5 calendar days if there is an SAE associated 
with the m edicat ion error (see Section 6.4) and wi thin 30 days for all other medicat ion errors.
6.8 Study governance and oversight
Safety of the pati ents in this clinical trial is closely monitored on an on -going basis by 
AstraZeneca representatives including the study  physician. After each sent inel cohort the SRB 
will review the blinded clinical data and AE and SAE data available aft er the 1 m onth fo llow-
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
71 (100)7.4 Storage
All study  drugs shoul d be kept in a secure place under appropriate storage condit ions.  The 
investigat ional product label on the vials specifies the appropriate storage.
7.5 Compliance
The administration of all study  drugs (including investigational products) should be recorded 
in the appropriate sections of the Case Report Form.
7.6 Accountability
The s tudy drug provi ded for thi s study  will be used only as directed in the Clinical Study  
Protocol .
The study  site staff will account for all study  drugs dispensed to the patient.
Study  site staff will account for all study  drugs received at the site, unused s tudy drugs and for 
appropriate destruction.  Certificates of delivery , destructi on shoul d be si gned.
7.7 Concomitant and other treatments 
The concomitant medicat ions not allowed at entry and/or during the study are listed below.
Table 7 Prohibited medication
Prohibited Medication/Class of drug:
Persantin or Asasantin.
Dipyridamole, Theophyllamine or 
FluvoxamineOngoing treatment at entry and during the study
7.7.1 Other concomitant treatment
Other medication other than that described ab ove, which is considered necessary  for the 
patient’s safet y and wellbeing, may be given at the discret ion of the Invest igator and recorded 
in the appropriate sections of the Case Report Form.
8. STATISTICAL ANALYSES BY ASTRAZENECA
8.1 Statistical considerations
 All personnel invo lved wit h the analysis o f the study  will remain blinded unt il 
database lock and Clinical Study  Protocol  violators i dentified.
 Analyses will be performed by AstraZeneca or its representatives.    
 Refer to Statist ical Analysis Plan (SAP) f or details
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
72 (100)A co mprehensive Statist ical Analysis Plan (SAP) will be prepared prior to the first patient in 
to the study . Any subsequent am endments to the SAP will be documented, with final 
amendments com pleted pri or to unblinding of the data for the analysi s. Details o f all analysis 
will be fully documented in the SAP.
The stati stical methodology  below describes the stati stical analysis as i t is foreseen when the 
study  is being pl anned.
If circumstances should arise during the study  rendering the analysis in appropri ate, or if in the 
meant ime improved methods of analysis should come to light, different analyses may be 
perform ed.
8.2 Sample size estimate
Due to the exploratory  nature of the study , the sampl e size is not based on formal statist ical 
considerations.  The sample size is based on experience from previous studies to obtain 
adequate safety , tolerabili ty and technical feasibilit y data to achi eve the obj ectives of the study  
while exposing as few patients as possible to study procedures.
It is estimated that 24 patients (8 per arm) need to be randomized and receive treatment in 
order to achieve 21 evaluable pat ients (7 per arm).
8.3 Definitions of analysis sets
8.3.1 Safety analysis set
The safet y analysis set will include all rando mized patients who received at least o ne inject ion 
of IP. Patients will be analysed according to the treatment which they  actually received. Any  
major deviat ions from  randomized treatm ent will be listed and considered when interpreting 
the safet y data.
Unless otherwise stated the safety  analys is set will be used for the presentation of all 
demographic and di sposi tion data, as well as all safet y analyses.
8.3.2 Exploratory analysis set
The exploratory  analysis set will consist of all randomized pat ients who received at least one 
inject ion of IP and fo r whom  at least one of the expl oratory  assessments i s available for pre -
dose and at least one post -dose measurement.
The available exploratory  data of pati ents excluded fro m the exploratory  analysis set will be 
listed only .
8.3.3 All Enrolled Patients
All enroll ed pat ients will include pat ients who have signed the informed consent form. 
Patients will  be analysed according to the treatment to which they  were randomized.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
73 (100)8.3.4 All Randomized Patients
All rando mized pat ients will include pat ients who were randomized. Pati ents will be analysed 
according to the treatment to which they were randomized.
8.4 Outcome measures for analyses
8.4.1 Safety variables
The primary  outcom e measures are safet y and tol erabili ty variables. They are listed below and 
in Section 5.2. This includes:
 Adverse events
 Vital signs (blood pressure, pulse, pulse oximetry )
 ECG
 Physical examinat ion 
 Laboratory  assessments (hematology , clinical  chemistry  and urinalysis). See Table 
2 and Table 3, Section 5.2.1
 Hem operi cardium  and/or tam ponade assessment, and LVEF wit h echocardiography
 Coagulation and use of conco mitant medicat ion
Addit ional safet y samples may  be collected if clinically indicated at the discret ion of the 
Invest igator. 
8.4.2 Exploratory variables
 15O PET parameters. The output variables, measured at baseline (pre CABG), 1 
and 3 m onths post CABG, will be
Regional sMBF in t he myocardi al regi on that received inject ions
Global sMBF
Regional MPR in the my ocardial  region that received inject ions
Global MPR 
 Echocardi ography  parameters. The output variables, measured at baseline (pre 
CABG), 1, 3 and 6 months post CABG, will be
Regional wall m otion (speckle tracking/vector velocit y derived strain) in the 
LV segments where IP was received, measured at baseline (pre CABG), 1, 3 
and 6 m onths post CABG.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
75 (100)Plasma concentration at visit 3 pre -surgery
AUC 0 -72 hours post dosing 
8.5 Methods for statistical analyses
Placebo data will be pooled throughout.
Dem ographic and baseline data will be summarized by  treatm ent and overall.
All statistical analyses and production of tables, figures and list ings will be performed using 
SAS versio n 9.2 or l ater.
If not otherwise specified, baseline refers to the last measurement prior to IP admi nistrati on.
8.5.1 Analysis of the primary variable (s)
Theanal
ysis and presentati on of  safety variables will be based on patients in the safet y 
analysis set. 
All safet y variables will be summarised by treatment group and visit using descript ive 
statist ics (n, mean, standard deviation [SD], median, minimum, and maximum for continuous 
data and abso lute and relat ive frequencies for categorical data). 
AEs will be summarised by treatm ent group, treatment related and severit y bymeans of 
counts summaries by Medical Dict ionary for Regulatory Activities(MedDRA) System  
Organ Class and Preferred Term (PT). 
Laboratory data for haematology and clinical chemistry will be summari zed by treatm ent 
group and visit. The number and percentages of patients with haematology  and clinical  
chemistry  treatment em ergent l aboratory  of changes wi th respect to normal ranges between 
baseline and post treatm ent will be tabulated. The incid ence of m arkedly abnorm al values 
and changes from baseline in the ECG parameters will be summarised by treatme nt group . 
Categorical outliers may bepresented bynumbers but need to be considered in context of 
inclusio n/excl usion criteria.Physical examinat ion and vital signs variables will be 
summarised by treatm ent group.
Unless otherwise stated, the fo llowing rul es will  apply to any  repeated safet y assessments:
If the repeated measurement of a specific parameter occurs prior to IP administration 
(Day  1),the last ob tained value prior to dosing will be used in the descriptive statist ics 
and in the calculat ion of changes from baseline.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
76 (100)8.5.2 Exploratory analysis 
The analysis and presentation of exploratory variables will be based on patients in the 
exploratory analysis set. 
All exploratory  variables will be summarised by treatment group and visit using descript ive 
statist ics (n, mean, standard deviation [SD], median, minimum, and maximum and geometric 
mean and geo metric SD if applicable for continuous data and absolute and relat ive frequencies 
for categori cal data). P -values will be unadjusted and tests will be two -sided.
Mean values per treatment will be plotted against visit.
Geom etric mean per treatment and individual plasma levels of VEGF
-A will be plotted 
against time after dosing. Calculat ion of VEGF AUC -Area under the concentration -time 
curve (μm ol*h/L) -will be done by  linear up/ l og down trapezoi dal summat ion. 
Change from baseline will be analysed for all exploratory  variables wit h baseline and post -
dose m easurements. Change from baseline for some exploratory  variables will be analysed 
using Analysis o f Covariance, (with treatment as fixed effect, patient as random effect and 
baseline value as covariates) or a repeated measurements model (with treatmen t, visit and 
treatm ent-
by-visit interaction as fixed effects, baseline as covariate and patient as random 
effect). If an approximat ion of the variable of interest fo llows a l og-norm al distribut ion rather 
than a norm al distribut ion, a logarithmic transforma tion of  the variable of interest will be 
done. All variables that are transformed will be back transformed for reporting.
9. STUDY AND DATA MANAG EMENT BY ASTRAZENECA
9.1 Training of study site staff
Before the first patient is entered into the study , an AstraZene ca representative will review and 
discuss the requirements of the Clinical Study  Protocol  and rel ated docum ents wi th the 
investigat ional staff and also train them in any study  specific procedures and the WBDC
system (s) utilised.
The Principal Invest igator will ensure that appropriate training relevant to the study  is given to 
all of these staff, and that any  new informati on relevant to the perform ance of this study  is 
forwarded to the staff invo lved.
The Principal Invest igator will maintain a record of all individuals invo lved in the study  
(medical, nursing and other staff).
9.2 Monitoring of the study
During the study , an AstraZeneca representative will have regular contacts with the study  site, 
including visits to:
 Provi de inform ation and support to the Invest igator(s)
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
77 (100) Confirm that facilit ies remain acceptable
 Confirm that the invest igational team  is adhering to the Clinical Study  Protocol , that 
data are being accurately and timely recorded in the CRFs, that bio logical samples 
are handled in accordance wi th the Laboratory  Manual and that study  drug 
accountabilit y checks are being performed
 Perform  source data verification (a comparison of the data in the CRFs wit h the 
patient’s medical records at the hospital or practice, and other records relevant to 
the study ) including verificat ion of informed consent of participat ing pat ients. Thi s 
will require direct access to all original records for each patient (e.g., clinic charts)
 Ensure withdrawal of informed consent to the use of the patient’s bio logical 
samples is reported and bio logical samples are i dentified and disposed of/destroyed 
accordingly, and the action is documented, and reported to the patient.
The AstraZeneca representative will be available between visit s if the Invest igator(s) or other 
staff at th e centre needs information and advice about the study  conduct.
9.2.1 Source data
Refer to the Clinical Study  Agreement for l ocati on of  source data.
9.2.2 Study agreements
The Principal Invest igator at each/the centre should comply wit h all the terms, condit ions, and 
obligat ions of the Clinical Study  Agreement, or equivalent, for this study .  In the event of any 
inconsistency between this Clinical Study  Protocol and the Clinical Study  Agreement, the 
terms of Clinical Study  Protocol  shall  prevail wi th respect to the con duct of the study  and the 
treatm ent of patients and in all other respects, not relat ing to study conduct or treatment of 
patients, the term s of the Clinical Study  Agreement shall prevail.
Agreements between AstraZeneca and the Principal Investigator should be in place before any  
study -
related procedures can take place, or patients are enrolled.
9.2.3 Archiving of study documents
The Investigator fo llows the principles outlined in the Clinical Study  Agreement (CSA).
9.3 Study timetable and end of study
The end o f the study  is defined as ‘the l ast vi sit of the last pati ent undergoing the study ’.
The study  may be terminated at individual centres if the study  procedures are not being 
perform ed according to GCP, or if recruit ment is slow.  AstraZeneca may also terminate th e 
entire study  prem aturely  if concerns for safety  arise wi thin this study  or in any other study  
with AZD8601.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
78 (100)9.4 Data management 
Data Management will be performed by a data management vendor per the Data Management 
Plan (DMP).
The data collected through thi rd party  sources will be obtained and reconciled against study  
data.
Adverse events and medical/surgical history  will be cl assified according to the termino logy of 
the latest version the Medical Dict ionary for Regulatory  Activit ies (MedDRA).  Medicat ions 
will be classified according to the WHO Drug Dictio nary.  All coding will be performed by  
the Data Management Vendor.
Data queri es will be raised for inconsistent, impossible or missing data.  All entries to the 
study  database will be available in an audit trail.
The data will be validated as defined in the Data Management Plan.  Qualit y control  
procedures will be applied to each stage of data handling to ensure that all data are reliable 
and have been processed correctly .  The Data Managem ent Pl an will also clarify the rol es and 
responsibilit ies of the various funct ions and personnel invo lved in the data management 
process.
When all data have been coded, validated, signed and locked, clean file will be declared.  Any  
treatm ent revealing data may  thereafter b e added and the final database will be locked.
Serious Adverse Event (SAE) Reconciliation
Where necessary SAE reconciliat ion reports are produced and reconciled with the Patient 
Safety database and/or the invest igational site. 
Data associated with human b iological samples
Data associated with bio logical samples will be transferred from laboratory  (ies) internal or 
external to AstraZeneca.
Management of external data
The data management vendor will receive and manage all external data according to the DMP.
10. ETHICAL AND REGULATO RY REQUIREMENTS
10.1 Ethical conduct of the study
The study  will be perform ed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Pract ice, applicable 
regul atory requi rements and the AstraZeneca policy  on Bi oethics and Hum an Bi ological  
Samples.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
79 (100)10.2 Patient data protection
The ICF will incorporate (or, in so
me cases, be accompanied by a separate document 
incorporating) wording that complies with relevant data protect ion and privacy legislat ion.
10.3 Ethics and regulatory review
An Ethi cs Committee should approve the final Clinical Study  Protocol , including the final 
versio n of the ICF and any  other wri tten information and/or materials to be provided to the 
patients.  The Invest igator will ensure the distribution of these documents to the applicable 
Ethics Co mmit tee, and to the study  site staff.
The opinio n of the Ethics Co mmittee should be given in writ ing. The Invest igator should 
submit the written approval to AstraZeneca before enro lment of any pat ient into the study . 
The Ethi cs Co mmittee should approve all advertising used to recruit patients for the study.
AstraZeneca should approve any  modificati ons to the ICF that are needed to meet local 
requi rements.
If required by local regulat ions, the Clinical Study  Protocol  shoul d be re -approved by  the 
Ethics Co mmit tee annually.
Before enrolment of any patient into the study , the final  Clinical Study  Protocol , incl uding the 
final versio n of the ICF, is approved by  the nat ional regulatory  authori ty or a notificat ion to 
the nat ional regulatory  authori ty is done, according to local regulat ions.
AstraZeneca will handle the distribut ion of any of these documents to the national regulatory  
authori ties.
AstraZeneca will provide Regulatory  Authori ties, Ethics Co mmit tees and Principal 
Invest igators with safety updates/reports according to local requirements.
10.4 Informed consent
The patients potentially eligible for this study , as assessed by  the review of Inclusion and 
Exclusio n criteria, will  be given wri tten and oral  inform ation about the study  and will be 
asked to sign the ICF for inclusion in the study . The m ain ICF will include consent for 
biological  sampling and for storage of biological samples for future research. 
The Principa l Invest igator(s) at each centre will:
 Ensure each patient is given full and adequate oral and written informat ion about 
the nature, purpose, possible risk and benefit of the study
 Ensure each patient is notified that they  are f ree to di scontinue fro m the study  at any  
time
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
80 (100) Ensure that each patient is given the opportunit y to ask questions and allowed time 
to consi der the inform ation provi ded
 Ensure each patient provides signed and dated info rmed consent before conducting 
any procedure specifically for the s tudy
 Ensure the original, signed ICF(s) is/are stored in the Invest igator’s Study  File
 Ensure a copy  of the signed ICF is given to the patient
 Ensure that any  incentives for patients who participate in the study  as well  as any  
provi sions for pati ents harme d as a consequence of study  parti cipat ion are described 
in the ICF that is approved by an Ethics Co mmittee.
10.5 Changes to the Clinical Study Protocol and Informed Consent 
Form
Study  procedures will not be changed without the mutual agreement of the Principal 
Invest igator and AstraZeneca.
If there are any substant ial changes to the Clinical Study  Protocol , then these changes will be 
docum ented in a new versio n of the study  protocol .
The new versio n of the Clinical Study  Protocol  is to be approved by  the relevan t Ethi cs 
Committee and if applicable, also the national regulatory  authori ty approval , before 
implementation.  Local requirements are to be fo llowed for new versio ns of Clinical Study  
Protocol s.
AstraZeneca will distribute any new versio ns of the Clinical Study  Protocol  to each Principal 
Invest igator (s). F or distribut ion to Ethics Co mmit tee see Secti on 10.3.
If a change to a Clinical Study  Protocol  requires a change to a centre’s ICF, AstraZeneca and 
the centre’s Ethics Co mmittee are to approve the revised ICF before the revised form is used. 
10.6 Audits and inspections
Authori sed representatives o f AstraZeneca, a regulatory  authori ty, or an Ethi cs Co mmit tee 
may perform  audi ts or inspect ions at the centre, including source data verificat ion.  The 
purpose of an audit or inspect ion is to sy stem atically and independent ly examine all study-
related activit ies and docum ents, to determine whether these act ivitieswere conducted, and 
data were recorded, analysed, and accurately reported according to the Clinical Study  
Protocol , Good Clinical Practice (GCP), guidelines of the Internat ional Conference on 
Harm onisat ion (ICH), and any  applicable regul atory  requirements .  The Invest igator will 
contact AstraZeneca immediately  if contacted by  a regul atory  agency  about an inspect ion at 
the centre.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
81 (100)11. LIST OF REFERENCES
Cohn JN et al 1993
Cohn JN, Johnson GR, Shabetai R, Loeb H, T ristani F, Rector T, Smith R, Fletcher R. Ejection 
fraction, peak exercise oxygen consumpt ion, cardiothoracic ratio, ventricular arrhythmias and 
plasma norepinephrine as determinants of prognosis in heart failure. Circulat ion 1993;87:VI -
5–VI-16
The CONSENSUS Trial Study Group 1987
The CONSENSUS T rial Study  Group. Effects of enalapril on mortalit y in severe CHF: results 
of CONSENSUS. N Eng J Med 1987;316: 1429 –1435
Dib N et al. 2011
Dib N, Khawaja H, Varner S, McCarthy  M, Cam pbell  A. Cell  Therapy  for Cardi ovascular 
Disease: A Com parison of Methods of Delivery. J. of Cardio vasc. Trans. Res. 2011; 4:177–
181
Djousse L et al. 2009
Djousse L, Driver JA, Gaziano JM. Relat ion between modifiable lifest yle factors and lifet ime 
risk of heart failure. JAMA 2009;302:394 -
400.
Ferrara N et al. 1991
Ferrara, N. , Houck, K. A., Jakeman, L. B., Winer, J. and Leung, D. W. The vascular 
endothelial growth factor family of po lypept ides. J. Cell. Biochem. 1991; 47: 211 –218.
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators 2016
GBD 2015 Di sease and In jury Incidence and Prevalence Co llaborators. Global, regional, and 
national incidence, prevalence, and y ears lived wi th disabili ty for 310 diseases and injuries, 
1990–2015: a systemat ic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 
388: 1545 –602
GBD 2015 Mortality and Causes of Death Collaborators 2015
Global, regi onal, and nati onal life expectancy , all-cause mortalit y, and cause
-specific 
mortalit y for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of 
Disease Study  2015, Lancet 2016; 388: 1459 –544
Go AS et al. 2013
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry  JD, Borden WB, Bravata DM, Dai 
S,Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard 
VJ,Huffman MD, Kissela B M,Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid 
D,Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS,Musso lino 
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
82 (100)ME, Nicho l G,Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong 
ND, Woo D, Turner MB. Heart dise ase and stroke statist ics–2013 update: A report from the 
American Heart Associat ion. Ci rculat ion 2013;127:e6
-245.
Karatolios et al. 2012
Karatolios K, Pankuweit S, Moosdorf RG, Maisch B. Vascular Endothelial Growth Factor in 
Malignant and Benign Pericardial Effusio n Clin. Cardio l. 2012; 35:377–381
Mathiasen A et al. 2015
Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer -Nielsen A, Ko foed KF, Haack-
Sørensen M, Ekblond A, Kastrup JBone marrow -derived mesenchymal stromal cell treatment 
in pa tients wi th severe i schaemic heart failure: a rando mized placebo -controlled trial (MSC -
HF tri al) European Heart Journal. 2015;36, 1744–1753
Hedman et al. 2009
Hedm an M, Muona K, Hedm an A, Kivelä A, Syvänne M, Eränen J, Rantala A, Stjernvall J, 
Nieminen MS, Harti kainen J, Yl ä-Herttuala S. Eight -year safety fo llow up of coronary  artery  
disease pat ients after l ocal intracoronary  VEGF gene transfer. Gene Ther 2009;16:629 –634.
Medical Advisory Secretariat 2010
Medical Advisory  Secretari at. Posi tron emissio n tomo graphy  (PET) f or the assessment of 
myocardial  viabili ty: an evidence -based analysis. Ont Health Techno l Assess Ser. 2010; 
10(16) 1 -
80.
Muona K et al. 2012
Muona K, Mäkinen K, Hedman M, Manninen H, Ylä -Herttual a S. 10 -year safet y follow-up in 
patients wi thlocal VEGF gene transfer to ischemic lower limb. Gene Ther 2012;19:392 –395.
Packer M et al. 1996
Packer M, Bristow MR, Cohn JN, Colucci WS,Fowl er MB, Gilbert EM, Shusterman NH.The 
effects of carvedilo l on m orbidi ty and mortali ty in patients wi th chroni c heart failure. N Eng J 
Med 1996;334:1349 –55
Parameshwar J et al. 1997
Param eshwar J, Keegan J, Sparrow J, Sutton GC, Poole -Wilso n PA. Predictors of prognosis in 
severe heart failure. Am Heart J 1992;123:421–6.
Pitt B et al. 1997
Pitt B, Segal R, Martinez FA,Meurers G, Cowl ey AJ, Thom as I, Deedwania PC, Ney 
DE,Snavely DB, Chang PI. Rando mised trial of lo sartan versus captopril in pat ients over 65 
with heart failure. (Evaluation o f Losartan in the Elderly  Study , ELITE). Lancet 
1997;349:747 –752.
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
83 (100)Rahimtool a SH 1985
Rahimtoola SH. A perspect ive on the three large mult icentre randomized clinical trials of 
coronary  bypass surgery  for chronic stable angina. Circulat ion 1985; 72(Suppl. 5), 123 –135 
Rahimtoola SH 1989
Rahimtoola SH. The hibernat ing myocardium . Am . Heart J. 1989; 117, 211
–221
Rosamond W et al. 2007
Rosam ond W, Fl egal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, 
Kissela B, Kissela B, Kittner S, Llo yd-Jones D, McDerm ott M, Mei gs J, Moy  C, Ni chol G, 
O'Donnell CJ, Roger V, Rumsfeld J, Sorlie P, Steinberger J, Thom T, Wasserthiel -Smoller S, 
Hong Y. Heart disease and stroke statist ics--2007 update: a report from the American Heart 
Associ ation Statistics Committee and Stroke Statistics Subco mmittee". Circulat ion. 115 (5): 
e69–171
Rose
ngart TK et al. 2013
Rosengart TK, Bishawi MM, Halbreiner MS, Halbreiner MS, Fakhoury  M, Finnin E, 
Hollmann C, Shroy er AL, Crystal  RG. Long -term follow-up of  a phase 1 trial o f angiogenic 
gene therapy  using di rect intramy ocardial  administ ration of  an adeno viral vector expressing 
the VEGF121 cDNA for the treatment of diffuse coronary  artery  disease. Hum  Gene Ther 
2013;24:203 –208.
Saraste A et el. 2017
Saraste A, Knuut i J. PET imaging in heart failure: the role of new tracersHeart Fail Rev. 2017; 
22(4):501 -
511 
Stirrup J et al. 2017
Stirrup	J,	Velasco	A,	Hage	FG,	Reyes	E,Comparison	of	ESC	and	ACC/AHA	guidelines	for	
myocardial	revascularization.	 J	Nucl	Cardiol .	2017;	24(3):	1046 –1053.
Task f orce for the diagnosis and treatment of chronic heart failure, European Society of 
Cardiology 2001
Task force for the diagnosis and treatment of chronic heart failure, European Society o f 
Cardi ology: Remme WJ, Swedberg K (cochairmen). Guidelines for the diagnosis and 
treatm ent of chroni c heart failure. Eur Heart J 2001;22:1527–1560.
Yancy CW et al. 2013
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci  
SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi  FA,McBride PE,
McMurray  JJV, Mitchell JE, Peterson PN, Riegel B, Sam F,Stevenson LW, Tang WWH, Tsai 
EJ, Wilko ff BL. 2013 ACCF/AHA Guideline for the Management of Heart Failure. 
Circulat ion.2013;128:e240 -e327
Clinical Study Protocol 
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
84 (100)Zangi L et al. 2013
Zangi L, Lui KO, von Gis e A, Ma Q, Ebina W, Ptaszek LM, Später D, Xu H, Tabebordbar M, 
Gorbatov R, Sena B, Nahrendorf M, Briscoe DM, Li RA, Wagers AJ, Rossi DJ, Pu WT, 
Chien KR. Modified mRNA directs the fate of heart progenitor cells and induces vascular 
regenerat ion after myoca rdial infarct ion. Nature Biotechno logy. 2013; 31,898 –907
Clinical Study Protocol Appendix A
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
85 (100)Appendix A Additional Safety Information
Further Guidance on the Definition of a Serious Adverse Event (SAE)
Life threatening
‘Life -threatening’ means that the patientwas at immediate risk of death from the AEas it 
occurred or it is suspected that use or continued use of the product would result in the 
patient’s 
death.  ‘Life -threatening’ does not mean that had an AEoccurred i n a m ore severe form  it 
might have caused death (e.g., hepatitis that resolved without hepatic failure).
Hospitalisation
Outpati ent treatm ent in an emergency room is not in itself a serious AE , although the reasons 
for it may be (e.g., bronchospasm, laryngeal  oedema).  Hospi tal admissio ns and/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
existed before the patientwas enrolled in the study, provided that it did not deteriorate in an 
unexpected way  during the study .
Important medical event or medical intervention
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situationswhere important medical events may  not be immediately life threatening or result in 
death, hospi talisat ion, disabili ty or incapaci ty but may jeopardize the patient or may  requi re 
medical intervention to prevent one or more outcomes listed in the definit ion of serious.  
These should usually be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used.
 Angioedema not severe enough to require intubation but requiring iv hydrocor tisone 
treatm ent
 Hepatotoxicit y caused by paracetamo l (acetaminophen) overdose requiring treatment 
with N-acetylcysteine
 Intensive treatment in an emergency room or at home for allergic bronchospasm
 Blood dy scrasias (e.g., neutropenia or anaemia requiring blood transfusion, etc.) or 
convulsio ns that do not result in hospitalisat ion
Development of drug dependency or drug abuse
A Guide to Interpreting the Causality Question
When making an assessment of causalit y consi der the fo llowing factors when deciding if there 
is a ‘reasonable possibilit y’that an AE m ay have been caused by the drug.
Clinical Study Protocol Appendix A
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
86 (100) Time Course.  Exposure to suspect drug.  Has the patient actually received the suspect 
drug?  Di d the AE occur i n a reasonable temporal relat ionship to the administration of 
the suspect drug?
 Consistency wit h known drug profile.  Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
 De-challenge experience.  Di d the AE resolve or improve on stopping or reducing the 
dose of the suspect drug?
 No al ternative cause.  The AE cannot be reasonably  explained by another aetio logy 
such as the underlying disease, other drugs, other h ost or environmental factors.
 Re-challenge experi ence.  Di d the AE reoccur if the suspected drug was reintroduced 
after having been stopped? AstraZeneca would not normally  recommend or support a 
re-challenge .
 Laboratory  tests.  A specific laboratory  invest igation (if performed) has confirmed the 
relationship .
In difficult cases, other factors could be considered such as:
 Is this a recogni zedfeature of overdose of the drug?
 Is there a known mechanism?
Causalit y of ‘related’ is m ade if fo llowing a revi ew of  the rel evant data, there is evidence for a 
‘reasonable possibilit y’of a causal relationship for the individual case.  The expressio n 
‘reasonable possibilit y’ of acausal relationship is meant to convey, in general
, that there are 
facts (evidence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgment.  With limited or insufficient information in the 
case, i t is likely  that the event(s) will be assessed as ‘not related’.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
Clinical Study Protocol Appendix C
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
87 (100)Appendix B International Airline Transportation Association (IATA) 6.2 
Guidance Document
Labelling and shipment of biohazard samples
International Airline Transportation Associat ion (IATA) classifies bio hazardous agents into 3 
categori es.  For transport purposes t he classificat ion of infectious substances according to risk 
groups was removed from the Dangerous Goods Regulat ions (DGR) in the 46th edit ion 
(2005).  Infect ious substances are now classified either as Category  A, Category  B or Exempt.  
There i s no di rectrelationship between Risk Groups and categories A and B.
Category A Infectious Substances are infect ious substances in a form that, when exposure to 
it occurs, i s capable of causing permanent disabilit y, life-threatening or fatal  disease in 
otherwi se heal thy humans or animals.  Category  A pathogens are e.g., Ebola, Lassa fever 
virus:
 are to be packed and shipped in accordance wit h IATA Instruction 602.
Category B Infectious Substances are infect ious Substances that do not meet the criteria for 
inclusio n inCategory  A.  Category  B pathogens are e.g., Hepatit is A, B, C, D, and E viruses, 
Hum an immunodeficiency virus (HIV) ty pes 1 and 2.  They  are assigned the following UN 
number and proper shipping name:
 UN 3373 –Biological Substance, Category  B
 are to be pa cked in accordance with UN3373 and IATA 650
Exempt -all other materials wit h minimal risk of containing pathogens
 Clinical trial samples will fall into Category  B or exempt under IATA regulations
 Clinical trial samples will routinely be packed and transpo
rted at ambient temperature 
in IATA 650 compliant packaging 
 Biological samples transported in dry  ice requi re addi tional dangerous goods 
specification for the dry -ice content
 IATA co mpliant courier and packaging materials should be used for packing and 
transportation and packing should be done by an IATA certified person, as applicable
 Samples routinely transported by  road or rail are patient to local regulat ions which 
requi re that they  are al so packed and transported in a safe and appropriate way  to 
contain any  risk of infect ion or contaminat ion by using approved couriers and 
packaging / containment materials at all times.  The IATA 650 bio logical  sample 
containment standards are encouraged wherever possible when road or rail transport is 
used.
Clinical Study Protocol Appendix C
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
88 (100)Appendix C Actions Required in Cases of Increases in Liver 
Biochemistry and Evaluation of Hy’s Law 
1. Introduction
This Appendix describes the process to be fo llowed in order to ident ify and appropri ately 
report Potential Hy’s Law (PHL) cases and Hy’s Law (HL) cases . 
It is not intended to be 
a com prehensive guide to the management of elevated liver biochemistries.
During the course of the study the Invest igator will remain vigilant for increa ses in 
liver biochemistr y. The Investi gator i s responsible for determining whether a patient 
meets PHL criteria at a ny point during the stu dy.
All sources of l aboratory  data are appropri ate for the determinat ion of PHL and HL 
events; this includes samples taken at scheduled study  visits and other visi ts incl uding 
central and all l ocal laboratory  eval uations even if collected outside of the study  visits; 
for example, PHL criteria could be met by  an elevated ALT from  a central  laboratory  
and/or elevated TBL from a local laboratory .
The Investigator will also review Adverse Event data (for example, for AEs that may 
indicate elevat ions in liver biochemistry ) for possible PHL events.
The Invest igator parti cipates, together with AstraZeneca clinical project representatives, in 
review and assessment of cases meet ing PHL criteria to agree whether HL criteria are met. 
HL cri teria are m et if there is no alternat ive explanation for the elev ations in liver 
biochemistry other than Drug Induced Liver Injury (DILI )caused by the Investi gational 
Medicinal Product (IMP).
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Serious Adverse Events (SAE) and Adverse Events (AE) according to the 
outcom e of the review and assessment in line wit h standard safe ty reporting processes.
2. Definitions
Potential Hy’s Law (PHL)
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 3x Upper Limit 
of Norm al (ULN) together with Total Bilirubin (TBL) ≥2xULN atanypoint during the 
study  following the start of study medicat ion irrespective of an increase in Alkaline 
Phosphatase (ALP).
Hy’s Law (HL)
AST or ALT ≥ 3x UL N together with TBL≥ 2xULN, where no oth er reason, other than 
the IMP, can be found to explain the co mbin ation of increases, e.g., elevated ALP 
indicat ing cholestasis, viral hepat itis, another drug.
Clinical Study Protocol Appendix C
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
89 (100)For PHL and HL the elevat ion in transaminases must precede or be coincident with (i.e. on 
the sam eday) the elevat ion in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
3. Identification of Potential Hy’s Law Cases
In order to ident ifycases ofPHL it is important to perform a comprehensive review 
of laboratory data foranypateint who meets a
ny of the following ident ificatio n 
criteria in iso lation or in co mbinat ion:
 ALT ≥3xULN
 AST ≥3xULN
 TBL ≥2xULN
The Investigator will wit hout delay review each new laboratory report and if the 
ident ificat ion criteria are met will:
 Notify the AstraZeneca representative
 Determine whether the patient meets PHL criteria (see Section 2 Definit ions wi thin 
this Appendix for definit ion) by reviewing laboratory reports fro m all previous 
visits
 Prom ptly e nter the l aboratory data into the laboratory CRF
4. Follo w-up
4.1 Potential Hy’s Law Criteria not met
If the patient does not meet PHL criteria the Investigator will:
 Inform the AstraZeneca representative that the patient has not met PHL criteria.
 Perform  follow
-up on subsequent laboratory resul ts according to the 
guidance provi ded in the Clinical Study Protocol.
4.2 Potential Hy’s Law Criteria met
If the patient does meet PHL criteria the Investi gator will:
Notify the AstraZeneca representative who will then inform the central Study Team
Within 1 day of PHL criteria being met, the Invest igator will report the case as an SAE 
of Potenti al Hy’s Law; seri ous cri teria ‘Important medical event’ and causalit y 
assessment ‘y es/related’ according to CSP process for SAE reporting .
Clinical Study Protocol Appendix C
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
90 (100)For subjects that met PHL criteria prior to starting IMP, the invest igator is not required 
to submit a PHL SAE unless there is a significant change #in the subject’s condit ion.
TheStudy Physician contacts the Invest igator, to provide guidance, discuss and agree 
an approach for the stu dy patients’ fo llow
-up (including any  further laboratory  testing) 
and the continuous review of data. 
Subsequent to this contact the Invest igator will:
Moni tor the patient until liver biochemistry param eters and appropri ate 
clinical symptom s and signs return to norm al or baseline levels, or as long, as 
medically indicated. Complete fo llow-up SAE Form as required.
Invest igate the aetiology of the event and perform diagnostic investigat ions as 
discussed wi th theStudy Physician.
Com plete the three Liver CRF Modules as information becomes available.
5. Review and Assessment of Potential Hy’s Law Cases
The instructions in this Section should be fo llowed for all cases where PHL criteria are met.
As soon as possible after the bi ochemistry abnormali tywas ini tiallydetected, the Study  
Physician contacts the Invest igator in order to review available data and agree on 
whether there is an alternat ive explanat ion for meeting PHL cri teria other tha n DILI 
caused bythe IMP, to ensure timely analysis and reporting to healt h authorit ies wit hin 15 
calendar day s from date PHL cri teria was met . The AstraZeneca Glo bal Clinical Lead or 
equivalent and Global Safet yPhysician will also be involved in this review together with 
other subject matter experts as appropriate.
According to the outcome of the review and assessment, the Investigator will fo llow 
the instructi ons bel ow.
Whether there is an agreed alternative explanation for the ALT or AST andTBL 
elevations, a determinat ion of whether the alternative explanat ion is an AE will be made 
and subsequent ly whether the AE m eets the cri teria for a SAE:
 If the alternat ive explanat ion is notan AE, record the alternative explanation on 
the appropriate CRF
 If the alternat ive explanat ion is an AE/SAE: update the previously submitted 
Potenti al Hy’s Law SAE and AE CRFs accordingly  with the new inform ation 
(reassessing event term; causalit y and seri ousness cri teria) fo llowing the AZ standard 
processes.
If it is agreed that there is no explanat ion that would explain the A LT or AST and TBL
Clinical Study Protocol Appendix C
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
91 (100)elevations other than the IMP:
 Send updated SAE (report term ‘H y’s Law’) according to AstraZeneca standard 
processes.
The ‘Medically  
Important’ serious criterion shoul d be used if no other 
serious cri teria apply
As there is no alternat ive explanation for the HL case, a causali tyassessm ent 
of ‘related’ should be assigned.
If, there i s an unavo idable dela y, of over 15 calendar day s in obtaining the informat ion 
necessary to assess whether or not the case meets the criteria for HL, then it is assumed 
that there is no alternat ive explanat ion unt il such time as an informed decisio n can be 
made:
 Provi des any  further update to the previously submitted SAE of Potential 
Hy’s Law, (report term now ‘Hy’s Law case’) ensuring causalit y assessment 
is related to IMP and seriousness criteria is medically important, according 
to CSP process for SAE reporting.
 Continue fo llow-
up and review according to agreed plan. Once the necessary 
supplementary informat ion is obtained, repeat the review and assessment to 
determine whether HL criteria are still met. Update the previously submitted PHL 
SAE report following CSP process for SAE reporting, according to the outcom e of 
the review and amending the reported term if an alternative explanat ion for the 
liver biochemistry elevat ions is determined.
References
Aithal et al 2011, Clinical Pharmacology and Therapeutics 89(6):806 -815.
FDAGuida nceforIndustry(issuedJuly2009) 'Drug -inducedliverinjury:Premarketing 
clinicalevaluation'
Clinical Study Protocol Appendix D
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
92 (100)Appendix D Kansas City Cardiomyopathy Questionnaire

Clinical Study Protocol Appendix D
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
93 (100)

Clinical Study Protocol Appendix D
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
94 (100)

Clinical Study Protocol Appendix D
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
95 (100)

Clinical Study Protocol Appendix E
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
96 (100)Appendix E Seattle Angina Questionnaire

Clinical Study Protocol Appendix E
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
97 (100)

Clinical Study Protocol Appendix E
Drug Substance AZD8601
Study Code D9150C00003
Version 5.0
Date 27 Feb 2020
98 (100)

Clinical Study Protocol Appendix E
Drug Substance AZD8601
Study Code D9150C00 003
Version 5.0
Date 27 Feb 2020
99 (100)

100 (100)
SIGNATURE PAGE
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic signature
Document Name: d9150c00003-csp-v5
Document Title: D9150C00003 Clinical Study Protocol version 5
Document ID: Doc ID-003605986
Version Label: 5.0 CURRENT LATEST APPROVED
Server Date
(dd-MMM-yyyy HH:mm ‘UTC’Z)Signed by Meaning of Signature
04-Mar-2020 09:55 UTC Content Approval
03-Mar-2020 12:09 UTC Content Approval
03-Mar-2020 11:15 UTC Content Approval
Notes: (1) Document details as stored in ANGEL, an AstraZeneca document management system.
